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ABSTRACT
Aging, a pathological factor in neurological injury
Aruvi Vijikumar, M.S.

One of the main reasons for CNS drugs to fail in clinical development is not considering
age as a risk factor while studying chronic age-related neurological/neurodegenerative
diseases in preclinical studies. We first set out to gain a comprehensive understanding of
the impact of age on various aspects (anatomical, immunological, and biochemical) in
rodents that play a key role in determining the onset, progression, and evolution of
disease severity. With advancing age, the vascular structure and function are
compromised which is hypothesized to accelerate cognitive decline. The initial step
toward developing novel therapeutics is to characterize the age-related vascular
modifications. Utilizing a vessel painting technique, we labelled the surface cortical
vessels of young and aged Sprague-Dawley rats and analyzed for classical angiographic
features (junctions, lengths, end points, density, etc). We found significant decrease in
vascular components while vascular complexity and lacunarity were significantly
increased in the aged brain compared to young brain. These age-dependent changes
were prominent at the level of right and left middle cerebral artery (MCA) as well as on a
global scale. Next, we investigated the changes on the peripheral immune response
following lipopolysaccharide (LPS) induced acute systemic inflammation in young and
aged Sprague Dawley rats. We observed age-related immunosuppression in the splenic
leukocytes indicative of reduced ability of the spleen to retain the immune cells. We also
found dysregulated cytokine/chemokine expression in the plasma following LPS
stimulation in aged and young animals. Interestingly, we noticed significant increase in
circulatory neutrophil population in the aged animals compared to young animals in
response to LPS at 24h. Taken together, these studies confirm the presence of agerelated modifications in the vasculature as well as immune system suggesting altered
response to injury/infection and thus emphasizing the need to utilize age-appropriate
models when studying diseases of the elderly. Lastly, we wanted to test the therapeutic
effect of a novel agent in case of brain injury model in aged rodents. Previous studies by
our lab and others have showed that targeting mitoNEET using NL-1 was neuroprotective
following brain injury models. We wanted to investigate if administration of NL-1 could
improve functional outcomes following stroke in an aged rodent model of cerebral
ischemia reperfusion injury. We found significant decrease in infarct volume and edema
index at 24h post stroke. We also saw enhanced survival and reduced behavior deficits.
Moreover, we showed improved BBB integrity, reduced oxidative stress and apoptosis at
72h post stroke. Interestingly, PLGA encapsulated NL-1 at 0.25mg/kg (which is 40-fold
lesser dose than NL-1 at 10mg/kg) produced better therapeutic effects. Future studies
should focus on understanding the mechanism underlying the biology of aging thus
enabling the development of novel therapeutic targets for neurological
disorders/diseases.

ACKNOWLEDGEMENTS
I would like to take a moment to reflect on the people who have supported and contributed
to the preparation and completion of this study.

First and foremost, I would like to thank my entire family who have always been there for
me. Thank you Amma and Appa for being my pillars of strength and constant support. I
am eternally grateful to my late grandfather who taught me values, morals and important
life lessons that has shaped me to into the person I am today. I am truly blessed and
thankful for my husband, Siddharth. Words can’t express my how much you mean to me.
Thank you very much for your patience and enduring support that encouraged me to
move forward. I would like to extend my thanks to my brother, in-laws, and the rest of my
family for their unwavering support throughout this journey.

I would like to thank my mentor and advisor Dr. Jason Huber for providing an opportunity
to carry out my dissertation in his lab. I am ever grateful for your valuable insight, wisdom,
and guidance throughout my training. Most importantly, thank you for teaching me how
to critique, think and write like a scientist!

I would like to thank Dr. Werner Geldenhuys for his constant support throughout my time
here at WVU. I am glad to have collaborated with your lab. You have been my second
mentor and were always there to help me out with anything at any time. I would like to
thank Dr. Tavakere Nagaraja for allowing me to visit your lab and help me progress with
the stroke surgeries. I would like to thank Dr. Mohammed Nayeem and Dr. Gordon
Meares for their valuable suggestions, expertise, and engagement. I would also like to

iii

thank my former committee member Dr. Elizabeth Engler-Chiurazzi for the initial training
and her extensive guidance on behavior studies.
I would like to thank the current and former members of the Huber’s and Geldenhuys’s
lab for providing a joyous and positive working atmosphere. Thank you to Maher
Shammaa for patiently teaching me rat handling and perfusion techniques. A big thanks
to Brandon Harvey for all his technical assistance with the flow experiments and tending
to the clinical calls early in the mornings. I couldn’t have done it without you! I would like
to thank Dr. Pushkar Saralkar and Jacob Boos for being awesome colleagues and for
their help and guidance during my PhD training.
I would like to thank my mentors from my master’s program in Germany, Dr. Stefan
Liebner and Dr. Kavi Devraj. Thank you for introducing me to the blood brain barrier
research and providing me with the tools I needed to pursue graduate studies in USA.

I would like to thank the WVU core facilities. Specifically, I am thankful to Dr. Amanda
Ammer from the microscope imaging facility, Dr. Terence McManus from the Metabolome
Analysis facility and Dr. Kathleen Brundage from the Flow cytometry core facility for their
training and expertise. Thank you to the OLAR staffs for taking care of the rats. I am truly
grateful for the administrative support and financial assistance provided by the School of
Pharmacy as well as WVU office of research and graduate education. A big thanks to Dr.
Julie Lockman, Dr. Lisa Salati, Joseph ‘Joe’ Andria, Connor Ferguson and Dr. Grazyna
Szklarz for making the transition to graduate school smooth for an international student.

iv

Finally, I would like to extend my heartfelt thanks to all my friends and colleagues who
have not only supported me throughout this journey but also provided a rich and positive
experience. Thank you to Stuti Khadka, Daniella Munezero, Fabliha Ahmed Chowdhury,
and Habibul Hassan Mazumder for making my lab experience wonderful. I owe special
thanks my close friend and flat mate Stephanie Agba for being my second family and
making this journey memorable. It was a pleasure having endless conversations not only
about science but also about food, culture, language, etc. A big thanks to Dr.
Rushendhiran Kesavan, Dr. Raj Vutukuri, and Elif Fidan for being my biggest
cheerleaders. I would like to thank my all friends and well-wishers from my school and
college for their constant support and encouragement.

Thank you very much everyone who have been a part of this amazing journey!

v

TABLE OF CONTENTS

ACKOWLEDGEMENTS..................................................................................................iii
LIST OF TABLES..........................................................................................................viii
LIST OF FIGURES..........................................................................................................ix
ABBREVIATIONS............................................................................................................x

CHAPTER 1: Introduction…………………………………………………………………….1
Literature Review………………………………………………………………………….….…2
Aging Epidemiology................................................................................................2
Hallmark signs of biological aging……………………………………………….……..3
Aging and neurological/neurodegenerative disorders………………………….……4
Therapeutic potential of pharmacological agents in age-related CNS diseases….7
Rationale…………………………………………………………………………………………9
Objectives………………………………………………………………………………………10

CHAPTER 2: Evaluating use of bryostatin-1 for the treatment of neurological
diseases and injury…………………………………………………………………………..14
Abstract…………………………………………………………………………………………15
Introduction.....................................................................................................................16
Bryostatin-1 in AD………………………………………….……………………………….....18
Bryostatin-1 in TBI……………………………………………………………………………..23
Bryostatin-1 in AIS……………………………………………………………………………..26
Bryostatin-1 in MS……………………………………………………………………………...28
Bryostatin-1 in neuro AIDS……………………………………………………………………30
Discussion………………………………………………………………………………………33
Conclusion……………………………………………………………………………………...38
Future studies…………………………………………………………………………………..38
CHAPTER 3: Characterization of age-related changes on cerebrovascular topology
in Sprague Dawley rats………………………………………………………………………42
Abstract…………………………………………………………………………………………43
vi

Introduction.....................................................................................................................44
Materials and Methods………………………………………………………………………..45
Results………………………………………………………………………………………….48
Discussion……………………………………………………………………….……………..50
Conclusion………………………………………………………………….……………….....57
Future Directions……………………………………………………………………………....57

CHAPTER 4: Characterization of age-related changes on leukocyte populations
following acute systemic inflammation in Sprague Dawley rats……………………..63
Abstract…………………………………………………………………………………………64
Introduction.....................................................................................................................65
Materials and Methods………………………………………………………………………..67
Results………………………………………………………………………………………….70
Discussion……………………………………………………………...………………………74
Conclusion…………………………………………………………………………………...…84
CHAPTER 5: Novel mitoNEET ligand NL-1 improves therapeutic outcomes in an
aged rat model of cerebral ischemia/reperfusion injury……………………………….91
Abstract…………………………………………………………………………………………92
Introduction……………………………………………………………………………………..93
Materials and Methods………………………………………………………………………..95
Results………………………………………………………………………………………...104
Discussion…………………………………………………………………………………….108
Conclusion…………………………………………………………………………………….115

CHAPTER 6: General discussion…………………………………………………………126
Summary………………………………………………………………………………………127
Future directions……………………………………………………………………………...131

References…………………………………………………………………………………...133

vii

LIST OF TABLES
2.1: Bryostatin-1 doses tested in rodent model of neurological diseases/disorders……..40
2.2: Bryostatin-1 doses tested in CNS clinical trials……………………………….………..41
4.1: Monoclonal antibodies for leukocyte characterization…………………………………90
4.2: LPS induced changes in body and spleen weight in the context of aging……………90
5.1: Health/sickness screen scale…………………………………………………………..124
5.2: Modified Neurologic Severity Scale (mNSS)…………………………………………125

viii

LIST OF FIGURES
Chapter 1
1.1: Age-related physiological changes occurring in the healthy brain……………………7

Chapter 2
2.1: Possible clinical applications of bryostatin-1 as a CNS drug………………………...18
2.2: Bryostatin-1 attenuated Aβ plaque deposition in Alzheimer’s disease in a PKCε
dependent pathway……………………………………………………………………….20

Chapter 3
3.1: Cerebral vasculature of rat brain visualized by vessel painting……………..………..59
3.2: Surface Cortical Analysis of Total Brain…………………………………….…………..60
3.3: Surface Cortical Analysis of Middle Cerebral Artery (MCA)………..…………………61
3.4: Vessel Diameter and Branch Order Analysis…………………………………………..62

Chapter 4
4.1: Schematic showing the processes involved in sample processing and analysis……85
4.2: Gating strategy to identify major leukocyte populations in aged and young rats…….86
4.3: Changes in circulating leukocytes after LPS challenge……………………………….87
4.4: Changes in splenic leukocytes after LPS challenge…………………………………..88
4.5: Plasma cytokine expression after LPS stimulation…………………………………….89

Chapter 5
5.1: Structure of the mitoNEET ligand, NL-1………………………………………….……117
5.2: Neurological assessment of NL-1 treatment at 24 h post-tMCAO…….……….…..118
5.3: Effect of NL-1 treatment on infarct volume and hemispheric swelling………….….119
5.4: Effect of NL-1 on iron accumulation in the brain………………………………….….120
5.5: Qualitative assessment of NL-1 treatment on IgG extravasation……………………121
5.6: Qualitative assessment of NL-1 treatment on 4-HNE protein adduct staining…….122
5.7: Effect of NL-1 treatment on apoptosis…………………………………………………123

ix

ABBREVIATIONS
4-HNE: 4-hydroxynonenal
ACA: Anterior Cerebral Artery
AD: Alzheimer’s Disease
ADME: Absorption, Distribution, Metabolism and Excretion
AIDS: Acquired Immunodeficiency Syndrome
AIS: Acute Ischemic Stroke
ALS: Amyotrophic Lateral Sclerosis
ANOVA: Analysis of Variance
APCs: Antigen Presenting Cells
ApoE: Apolipoprotein E
APP: Amyloid Precursor Protein
ARV: Antiretroviral Drugs
ATP: Adenosine Triphosphate
Aβ: Amyloid Beta
BBB: Blood-Brain Barrier
BDNF: Brain Derived Neurotrophic Factor
bEnd3: Murine Brain Vascular Endothelial Cells
BETi: Bromodomain Inhibitors
cART: Combination Antiretroviral Therapy
CBF: Cerebral Blood Flow
CH: Contralateral Hemisphere
CIV: Corrected Infarct Volume
CNS: Central Nervous System
CVD: Cerebrovascular Diseases
DAG: Diacylglycerol
DAPI: 4',6-diamidino-2-phenylindole
DCs: Dendritic Cells
Dil: 1,1’-dioctadecyl-3,3,3’,3’ tetramethylindocarbocyanine perchlorate
EAE: Experimental Autoimmune Encephalomyelitis
ELISA: Enzyme-linked Immunosorbent Assay
FDA: Food and Drug Administration
FITC: Fluorescein Isothiocyanate
GPCR: G-protein coupled receptors
HAND: HIV-Associated Neurocognitive Disorders
HIV: Human Immuno deficiency virus
HRP: Horseradish Peroxidase
HT: Hemorrhagic Transformation
ICU: Intensive Care Unit

x

IFN-: Interferon-gamma
IH: Ipsilateral Hemisphere
IHC: Immunohistochemistry
IL: Interleukin
IL1β: Interleukin 1 beta
IRI: Ischemia-reperfusion injury
LC-MS/MS: Liquid Chromatography-Mass Spectrometry
LPS: Lipopolysaccharide
LRA: Latency Reversal Agent
MCA: Middle Cerebral Artery
MMP-9: Matrix Metalloproteinases-9
MMSE: Mini-Mental State Examination
mN: MitoNEET
MnSOD: Manganese Superoxide Dismutase
mNSS: Modified Neurological Severity Scores
MS: Multiple sclerosis
NK: Natural Killer
NL-1: NEET Ligand 1
NP: Nanoparticles
NVU: Neurovascular Unit
PBS: Phosphate Buffered Saline
PCA: Posterior Cerebral Artery
PD: Parkinson’s disease
PFA: Paraformaldehyde
PKC: Protein kinase C
PLGA: poly D,L-lactic-co-glycolic acid
PPAR: Peroxisome Proliferator-Activated Receptor Gamma
ROS: Reactive Oxygen Species
rTEM: Reverse Transendothelial Migration
SD: Standard Deviation
SEM: Standard Error of the Mean
TBI: Traumatic Brain Injury
TLR-4: Toll-like Receptor 4
tMCAO: Transient Middle Cerebral Artery Occlusion
TNF-α: Tumor Necrosis Factor α
tPA: Tissue Plasminogen Activator
TTC: Triphenyltetrazolium Chloride
TUNEL: Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling
ZO-1: Zonula Occludens-1

xi

CHAPTER ONE
Introduction

1

LITERATURE REVIEW

Aging epidemiology
The world’s population is aging at an alarming rate. In 2019, it was estimated that
there were 703 million people aged 65 or over worldwide and this number is expected to
surpass 1.5 billion by 2050, that is about 25% of the world’s population (Nations et al.,
2019). In the US alone, the older population (aged≥65 years) is projected to expand from
53 million in 2018 to 88 million in 2050 (Hou et al., 2019). In addition to well developed
nations, less developed nations will also see a surge in their older population (Preston
and Stokes, 2012; Shetty, 2012; Fernández-Ruiz, 2019). Reports predict one in five
people in underdeveloped nations will be over 60 years old by 2050 (Shetty, 2012). The
sources of such growth in aging population are found to be due to changing patterns of
fertility, mortality, and migration (Preston and Stokes, 2012). Additionally, the average
human life expectancy due to improvements in health care has drastically increased over
the years (Cuny, 2012; Fernández-Ruiz, 2019; Aburto et al., 2020). The life-expectancy
of Americans is estimated to increase by about 7.4% in the next ~40 years, i.e., from 79.7
in 2017 to 85.6 in 2060 with women expected to live longer than men on an average, in
2060 (Medina et al., 2020). However, this rise in life span is not directly proportional to
the quality of life, showing only a modest increase in the years spent without disability
(Aging and Metabolism: Two Sides of the Same Coin, 2017). This is due to the fact that
there is a surge in global burden of late-life diseases and is associated with increased
incidence and prevalence of geriatric neurodegenerative diseases in older individuals
(Cuny, 2012; Callixte et al., 2015; Baker and Petersen, 2018; Partridge et al., 2018;
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Fernández-Ruiz, 2019). As we progress towards increasingly aged population, mortality
due to all causes increases exponentially (Parsons, 2007). In the recent years, the
number of critically ill elderly patients admitted to the intensive care unit (ICU) have not
only increased (Esme et al., 2019) but also have low hospital survival rate when compared
to young patients (Topeli and Cakir, 2013). The financial cost of providing long-term care
for geriatric patients imposes a huge economic burden on the health care sector (Florence
et al., 2018). Therefore, understanding the biology of aging and age-related diseases is
of utmost importance and emphasize the need for developments and advances to
improve the quality of life in elderly by slowing the biological aging process.

Hallmark signs of biological aging

Biological aging is clearly distinct from chronological aging and is considered as a
complex, dynamic physiological process. It is linked to physical, metabolic, cognitive, and
emotional aspects of individual function (Bland, 2018). With progression of time, genetic,
epigenetic and environmental factors lead to accumulation of aberrant molecular
mechanism at cellular, molecular and organization level thereby altering the physical
appearance, functionality and regenerative capacity of an organism (Khan et al., 2017;
Hou et al., 2019). Hence, it is necessary to identify the molecular and cellular processes
underlying the complex physiological process of biological aging. Over the years, studies
have identified nine hallmark signs of aging which are classified into three categories
namely, the primary, antagonistic and integrative (López-Otín et al., 2013). The primary
hallmark constitutes the main driving force of aging, consisting of genomic instability,
telomere attrition, epigenetic alterations, and loss of proteostasis. The second
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antagonistic hallmarks, associated with mitochondrial dysfunction, cellular senescence
and deregulated nutrient sensing, provide benefits at low levels and become detrimental
at high levels. Finally, the integrative hallmarks which comprise stem cell exhaustion and
altered intercellular communication induce damage beyond repair due to pro-longed
accumulation (López-Otín et al., 2013, 2016; Hou et al., 2019). This system of
identification of the hallmark signs of aging has aided in the development of novel
therapeutic targets aiming to restore the functional decline seen in aged individuals.

Aging and neurological/neurodegenerative disorders
Neurological/Neurodegenerative disorders are diseases affecting the central
nervous system (CNS) classified by death of neurons leading to functional and cognitive
decline (Mayne et al., 2020). Neuronal loss may be progressive as in the case of
Alzheimer’s Disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS) (Dugger and Dickson, 2017) or can be caused due to primary insult such as
demyelination, ischemia or trauma leading to secondary neurodegeneration as in the
case of multiple sclerosis (MS), acute ischemic stroke (AIS) and traumatic brain injury
(TBI) (Mayne et al., 2020). Neurodegenerative diseases are one of the most lifethreatening disorders around the world, predominantly affecting the elderly (Niccoli and
Partridge, 2012a; Harris et al., 2014; Fülöp et al., 2016; Kowalska et al., 2017; Hou et al.,
2019;

Azam

et

al.,

2021).

Among

the

several

risk

factors

for

neurodegenerative/neurological disorders, the aging process itself imposes a significant
impact (Niccoli and Partridge, 2012a; López-Otín et al., 2013; Callixte et al., 2015; Hou
et al., 2019; Azam et al., 2021; Wrigglesworth et al., 2021).
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There is a close association between aging and age-related diseases at molecular,
cellular and organization level. With advancing age, the brain undergoes several changes
(Figure 1.1). Normal brain aging is characterized based on progressive changes in local
reductions in glucose metabolism, impaired cellular calcium signaling, oxidative stress,
accumulation of damaged and misfolded proteins, mitochondrial dysfunction leading to
aberrant energy metabolism, chronic low grade inflammation, and neuronal atrophy
driven by defective activity at synapses (e.g. receptors, transporters, ion channels and
synthetic enzymes) (Rango and Bresolin, 2018; Erickson and Banks, 2019; FernándezRuiz, 2019; Hou et al., 2019; Mayne et al., 2020; Blinkouskaya et al., 2021). Additionally,
there is increased glial reactivity (increased astrogliosis and microglia activation)
exacerbating neuroinflammation as well as decreased neurogenesis concurrent with
significant loss of neurons (Fernández-Ruiz, 2019; Hou et al., 2019; Mayne et al., 2020;
Blinkouskaya et al., 2021). The microvasculature of the CNS is composed of tightly
regulated endothelial cells forming the blood brain barrier (BBB) whose function is to
protect the brain against circulating toxins or pathogens (Daneman and Prat, 2015;
Profaci et al., 2020). Recent studies have demonstrated increased blood brain barrier
permeability in certain brain regions of older cohorts suggesting BBB disruption as a part
of the normal aging process (Goodall et al., 2018; Verheggen et al., 2020). Moreover,
noninvasive brain imaging studies have revealed age-related changes on the brain
morphology (specific structures as well as different anatomical regions), along with
vascular morphology (Abdelkarim et al., 2019; Nyberg and Wåhlin, 2020; Beishon et al.,
2021). Several studies showed the rate of increase in cerebral atrophy, the most
important morphological change, with aging (Blinkouskaya and Weickenmeier, 2021;
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Blinkouskaya et al., 2021). This is associated with decline in global brain volume, white
matter volume, brain folding, emergence of white matter lesions, gray matter shrinking,
sulcal widening, thinning of the cortex, and ventricular enlargement (Blinkouskaya and
Weickenmeier, 2021; Blinkouskaya et al., 2021). Apart from global structural alterations,
the brain vascular components undergo remodeling with age resulting in changes in
cerebral blood flow (CBF) and concurrent neurovascular coupling dysfunction
(Abdelkarim et al., 2019; Beishon et al., 2021; Mokhber et al., 2021). In addition, recent
studies demonstrated higher activity in certain brain regions during rest and cognitive
tasks which might be a compensatory mechanism for reduced functional connectivity in
older subjects (Sala-Llonch et al., 2015; Hughes et al., 2020). Consequently, disrupted
functional architecture of brain networks along with vascular dysfunction leads to the
cognitive impairment in the elderly (Sala-Llonch et al., 2015; Damoiseaux, 2017;
Abdelkarim et al., 2019; Hughes et al., 2020; Beishon et al., 2021; Mokhber et al., 2021).
Taken together, these normal age-related physiological changes are exacerbated during
pathological conditions leading to onset and rapid progression of the disease state.
Understanding the biology of normal aging is not only useful in predicting the disease
severity but also important for successful development of therapeutic interventions for the
treatment of neurodegenerative/neurological diseases in the elderly.
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Figure 1.1: Age-related physiological changes occurring in the healthy brain.
Created with BioRender.com

Therapeutic potential of pharmacological agents in age-related CNS diseases
The pipeline of drug discovery and development process is an expensive one apart
from being time consuming. Currently, it is estimated about $113 million to over $6 billion
dollars required on an average for each novel drug to be approved for clinical use
(Rennane et al., 2021). However, studies reported that 90% of the drug candidates fail to
advance during clinical trials and drug approval even after rigorous optimization and
validation at preclinical stage (Hingorani et al., 2019; Sun et al., 2022). In general, the
failure rate is higher (close to 100%) for CNS targeting drugs especially in case of major
neurodegenerative diseases, in both preclinical and clinical studies (Gribkoff and
Kaczmarek, 2017; Cummings et al., 2019; Howes and Mehta, 2021). For example, till
date the only food and drug administration (FDA) approved pharmacological agent to treat
ischemia stroke is reperfusion with tissue plasminogen activator (tPA) despite 1000+
7

successful preclinical studies (O’Collins et al., 2006; Dhir et al., 2020; Lourbopoulos et
al., 2021). Owing to the high failure rate, longer time for drug development process and
post-development regulatory review, major pharmaceutical companies are moving away
from CNS drug development process (Gribkoff and Kaczmarek, 2017; Howes and Mehta,
2021). In case of AD, there are currently only 126 molecular entities in clinical trials as
opposed to 3558 agents in cancer clinical trials (Moser and Verdin, 2018; Cummings et
al., 2021). As a consequence of expensive drug development failure, a huge burden is
imposed on not only the healthcare providers but also the citizens through healthcare
taxation (Hingorani et al., 2019). With the growing older population and increased
prevalence of chronic neurodegenerative diseases (Baker and Petersen, 2018; Partridge
et al., 2018), there is an urgent need to develop CNS drugs in a timely manner by reducing
the cost and time associated with the clinical trials (Cummings et al., 2021). Additionally,
the success rate of clinical trials can be improved by identifying the right drug, druggable
target, biomarkers, recruiting the right participants, predicting those at the high risk
category for disease development as well as starting treatment at the right age (Baker
and Petersen, 2018; Cummings et al., 2019).
Aging is associated with increased co-morbidities. The prevalence of
multimorbidity (the coexistence of multiple chronic diseases) in older individuals ranges
from 55 to 98% from a global perspective (Marengoni et al., 2011). In the US, it is said
that six in ten adults have at least one chronic disease and four in ten adults have two or
more (Maresova et al., 2019). As a consequence of higher prevalence of chronic disease,
the number of drugs taken by aged individuals tend to be higher than younger individuals.
A recent survey showed that about 69% of aged adults (40-79 years) consumed at least
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one prescription drug and 22.4% consumed at least 5 prescription drugs in the US (Hales
et al., 2019). Studies have shown that aging alters the pharmacokinetic and
pharmacodynamic properties of a drug (Mangoni and Jackson, 2004; Drenth-van Maanen
et al., 2020). A study conducted in rats showed decreased clearance, volume of
distribution, potency and increased elimination half-life for a serotonin receptor
antagonist, lerisetron with aging (Jauregizar et al., 2003). In addition, age-related
differences exist in disease-relevant systems and thus significantly influence the
outcomes of studies examining the mechanism of drug action, drug efficacy, drug toxicity
as well as biology of disease (Jackson et al., 2017). Apart from the underlying mechanism
of biological aging, several age-related physiological changes accompanying dementia
and frailty can alter the pharmacokinetics of medications (Drenth-van Maanen et al.,
2020). Loss of body weight and muscle mass can inadvertently decrease the volume of
distribution of hydrophilic drugs while increasing the volume of distribution of hydrophobic
drugs (Drenth-van Maanen et al., 2020). Additionally, age related dementia is associated
with increased BBB permeability and decreased efflux pump activity which results in
neurotoxicity for certain drugs (Reeve et al., 2015, 2017). Despite these differences, aged
individuals are frequently excluded from clinical trials. For example, only a small fraction
of people >50 years have been included in human trials while testing antiretroviral drugs
(Budak, 2020).

RATIONALE
Despite the existence of several animals to study human diseases, finding the right
model that fully recapitulates the disease pathophysiology or phenotype continues to be
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a problem (Nielsch et al., 2016). Rodent models are the most commonly used mammals
in biomedical research and non-clinical drug trial (Jackson et al., 2017). Multitude of
factors affect the outcome of a study of which age of the animals have a significant impact
on new drug candidates and is associated with altered drug handling, physiological
reserve, and pharmacodynamic responses (McLean and Le Couteur, 2004; Ettlin et al.,
2010). Inconsistent choice of age while studying specific age-related diseases in rodent
models negatively impacts the quality of the research and leads to failure of translation of
drugs from bench to bedside (Jackson et al., 2017). Therefore, there is an urgent need to
understand the influence of age on various aspects (anatomical, immunological, and
biochemical) in rodents that play a key role in determining the etiology, progression,
prognosis of age-related chronic disease.

OBJECTIVES
The overarching goal of this dissertation was to characterize the influence of age on
anatomical, immunological, and biochemical aspects and its impact on therapeutic
outcomes in the context of age-related neurological disorders.

Chapter

2:

Pharmacological

profile

of

bryostatin-1

in

various

CNS

diseases/disorders
Our lab is primarily interested in testing the therapeutic potential of pharmacological
agents in aged rodent models of brain injury/neurodegenerative diseases. One such
pharmacological agent that our lab focused on was bryostatin-1, an ultra-potent protein
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kinase C (PKC) modulator. The pharmacological profile of bryostatin-1 in various CNS
diseases/disorders has been well studied by our lab and others and thus reviewed here.

Chapter 3: Characterize the effect of aging on cerebrovascular architecture
Age-related changes on the vascular morphology have been implicated in several
cerebrovascular and neurodegenerative diseases. Reduction in vessel density with aging
is correlated with reduced cerebral blood flow (CBF), neuro vascular coupling, impaired
cellular metabolism. However, it is not known at what level these changes are taking
place. To investigate that, we employed a vessel painting technique to label the surface
cortical endothelial cells. Using aged and young Sprague Dawley rats, we measured agerelated changes on the classical vessel parameters, complexity, vessel diameter and
order of branching of the middle cerebral arteries as well as global surface cortical
vessels. Given the association between cerebral vessel structure and cognition, the
results of the study would provide a detailed characterization of vessel architecture with
age in vivo and may help elucidate the cognitive changes during senescence.

Chapter 4: Characterize the effect of age on peripheral immune response following
lipopolysaccharide (LPS) induced systemic inflammation
With advancing age, our immune system undergoes cellular and functional alterations
characterized by immunosenescence and chronic low-grade inflammation termed as
inflamm-aging. Several studies have reported age-related changes in innate and adaptive
arms of immunity. However, changes in the composition of leukocytes in response of
injury/infection in an aged subject is unknown. We used LPS induced systemic
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inflammation model to determine the influence of age on acute immune response at 3
and 24h in young and aged Sprague Dawley rats. We performed flow cytometry to
investigate the age-related changes in major leukocyte population in blood and spleen.
We also analyzed the cytokine expression following systemic inflammation using enzymelinked immunosorbent assay (ELISA). Given the importance of peripheral immune system
in the pathological progression of neurodegenerative diseases, the results of this study
would provide evidence for age-related alterations in blood and splenic leukocyte
composition as well circulating cytokine/chemokine profiles. Given the role of peripheral
immune system in driving neuroinflammation, the knowledge gained from this study would
aid in comprehending the pathological progression of neurodegenerative diseases in
elderly.

Chapter 5: Investigate the therapeutic potential of a novel mitoNEET ligand, NL-1
in an aged rodent model of brain injury (cerebral ischemia/reperfusion injury
model)
Cerebral ischemia is the leading cause of mortality and morbidity predominantly affecting
the elderly. While recanalization of the ischemic brain with tissue plasminogen activator
(tPA) and endovascular thrombectomy can restore the blood flow and salvage the brain
tissue, they can do more harm than good due to ischemia-reperfusion injury (IRI). Among
the various pathological mechanisms of ischemia-reperfusion injury, mitochondrial
dysfunction due to free radical production plays a pivotal role in orchestrating neuronal
damage and serves as a potential therapeutic target. Prior studies demonstrated that
targeting MitoNEET (mN), an iron- sulfur cluster protein located in the outer mitochondrial
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membrane that acts a redox senor, by using the ligand NL-1 produces significant tissue
sparing and neuroprotective effects following ischemic stroke, traumatic brain injury &
Parkinson’s disease. Here we hypothesized that targeting mN activity following cerebral
ischemia reperfusion injury would reduce ischemic brain injury & improve neuronal
survival in the penumbra region surrounding the infarct by reducing lipid peroxidation
induced cellular damage. We evaluated the efficacy of NL-1 and a nanoparticle
formulation of NL-1 in treating cerebral ischemia/reperfusion injury using aged female rats
following a 2 h middle cerebral artery occlusion (MCAO) with reperfusion. The results of
this study would demonstrate that mN is a novel druggable target in the case of cerebral
ischemia/reperfusion injury that requires further investigation.

In summary, this dissertation evaluates the function of age as a non-modifiable risk
factor for neurological disorders. This dissertation emphasizes the need to understand
and characterize the effect of age on brain vessel structure as well as the peripheral
immune system following systemic inflammation in a quantitative manner. Additionally,
this body of work also documents the therapeutic efficacy of a novel ligand NL-1, targeting
mitochondrial protein mN in an aged rodent model of cerebral ischemia reperfusion injury.
Overall, this work underscores the importance of using aged rodents while studying agerelated diseases to enhance the success rate of clinical drug development.
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CHAPTER TWO
Evaluating use of bryostatin-1
neurological diseases and injury
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for

the

treatment

of

ABSTRACT
Protein kinase C (PKC) isozymes are a family of kinases that regulate many downstream
signaling processes and play vital roles in human health and disease. Owing to their
involvement in key biological events such as signal transduction, cell proliferation and
apoptosis, PKC isozymes have become attractive drug targets. Bryostatin-1, a
macrocyclic compound obtained from the marine organism Bugula neritina, is an ultrapotent PKC modulator with high affinity for PKC isozymes alpha, delta and epsilon. In
recent years, preclinical and clinical studies have shifted away from probing bryostatin-1
as an anti-cancer drug and instead have shifted focus to the promising pharmacological
benefits of bryostatin-1 as a neuroprotective agent for central nervous system diseases.
The purpose of this mini-review is to discuss the latest findings advancing the
pharmacological potential of bryostatin-1 for the treatment of neurological diseases,
including Alzheimer’s disease, traumatic brain injury, ischemic stroke, multiple sclerosis
and neuroAIDS.
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INTRODUCTION
Bryostatins, isolated from marine bryozoans Bugula neritina, are highly complex
oxygenated macrocyclic lactones that were initially studied as anti-cancer compounds
due to their anti-tumorigenic and cytotoxic profiles in murine lymphocytic leukemia cells
(Pettit et al., 1982). Bryostatins demonstrate a wide range of anti-cancer effects, including
immune stimulation, growth inhibition and antineoplastic effects on multiple malignancies
(Wu et al., 2020). Of the isolated 21 analogs, bryostatin-1 is the most well-studied and
pharmacologically characterized (Wu et al., 2020). Bryostatin-1 is a potent PKC regulator
with strong binding affinity (Ki=0.6-2.1nM) for PKC isozymes alpha (α), beta (), delta (δ),
gamma (), epsilon (ɛ), eta (), theta () which are determined using a cell free assay (Ly
et al., 2020). In particular, bryostatin-1 has strong efficacy towards PKCɛ with
displacement of phorbol ester, the prototypical exogenous ligand for PKC, occurring at
sub-nanomolar concentrations in rodents and humans (Hess et al., 1988). Both
conventional and novel PKC isozymes have shown varied function and dose-dependent
regulation when exposed to bryostatin-1 while atypical PKC isozymes do not bind to
bryostatins (Szallasi et al., 1994; Mutter and Wills, 2000).
The pharmacological activity of bryostatin-1 involves allosteric modulation of PKC
by binding to their regulatory C1 domains ((C1a and C1b), mimicking the action of
endogenous ligand diacylglycerol (DAG). This binding drives the conformational change
of the PKCs thus potentiating the transient binding of PKC to the plasma membrane and
increasing the activation of downstream signaling cascades (Wender and Staveness,
2014). While low concentrations of bryostatin-1 stimulate PKC activity, studies on cancer
cells show that upon prolonged exposure to bryostatin-1 at high concentrations, PKC
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expression undergoes downregulation via ubiquitin-mediated proteasomal degradation
(Mutter and Wills, 2000; Sun and Alkon, 2006). This unique biological activity of
bryostatin-1, as an activator and inhibitor of PKC activity, at different concentrations and
exposure intervals, provides unique opportunities for studying PKC activity and should be
considered when developing dosing schemes for bryostatin-1.
After bryostatin-1 is administered, it is widely distributed in the body and well
tolerated with the most common adverse effect being myalgia (Zhang et al., 1996; Mutter
and Wills, 2000; Sun and Alkon, 2006). For more than 20 years, multiple Phase I/II clinical
trials for solid and hematological malignancies have been conducted with bryostatin-1
alone and in combination with other chemotherapeutic agents (Kollár et al., 2014). While
bryostatin-1 showed absence of tumor-promoting activity in contrast to other PKC
activators, it did not progress to Phase III clinical trial as an anti-cancer drug (Kollár et al.,
2014; Raghuvanshi and Bharate, 2020).
In the early 2000s, studies began showing promising results with bryostatin-1 as a
CNS drug (Figure 2.1). These pharmacological studies of bryostatin-1 focused on its
action in stimulating synapse formation, release of neurotrophic factors, enhanced
learning capacity and consolidation of memories (Sun and Alkon, 2006, 2014; Kollár et
al., 2014). Bryostatin-1 has also been reported to have anti-inflammatory and antioxidative properties that mitigate cellular stress and neuroinflammation (Kornberg et al.,
2018; Safaeinejad et al., 2018). Recently, studies using bryostatin-1 treatment following
ischemic stroke and traumatic brain injury demonstrated pronounced reductions in edema
formation and marked decreases in blood-brain barrier (BBB) disruptions (Tan et al.,
2013, 2015; Lucke-Wold, Logsdon, et al., 2015), which led our lab to postulate that
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bryostatin-1 confers neuroprotection following brain injury, in part, by restoring functional
integrity of the BBB (Tan et al., 2013, 2015; Lucke-Wold, Logsdon, et al., 2015). In this
review, we discuss recent advances in the therapeutic use of bryostatin-1 to treat
neurological diseases/disorders with a specific focus on Alzheimer’s disease (AD),
traumatic brain injury (TBI), acute ischemic stroke (AIS), multiple sclerosis (MS) and
reversing latency of human immunodeficiency virus (HIV).

Figure 2.1: Possible clinical applications of bryostatin-1 as a CNS drug. A number
of preclinical and clinical studies have recently focused on the therapeutic applications of
bryostatin-1 in Alzheimer’s disease (AD), traumatic brain injury (TBI), acute ischemic
stroke, multiple sclerosis (MS) and neuroAIDS. See text for detail.

BRYOSTATIN-1 IN AD
AD is a chronic neurodegenerative disease characterized by progressive dementia
that affects over 17 million people globally (Schrott et al., 2015). With advancing age, the
incidence and prevalence of AD is increasing and thus causing a surge in mortality and
morbidity worldwide (Sawda et al., 2017). The progression of age-related incidence of AD
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is 15% in the age group of 60–64 to 85–89 years (Fernández-Ruiz, 2019). In the US, it is
estimated that 6.2 million individuals are currently living with AD dementia, and is
predicted to increase to more than 13.8 million by 2060 (2021 Alzheimer’s disease facts
and figures, 2021). Pathological hallmarks associated with AD include deposition of
amyloid beta (Aβ) plaques, formation of neurofibrillary tangles, progressive loss of
synapses and marked neurodegeneration (Sadigh-Eteghad et al., 2015; Nelson et al.,
2017).
Secretases (α-, β- and γ-) are proteases that process amyloid precursor protein
(APP) and play a pivotal role in generation and modulation of Aβ peptide (Ahmad et al.,
2019). A leading hypothesis for the pathogenesis of AD posits that AD-associated
neuronal dysfunction and cognitive decline is due to extracellular accumulation of Aβ
protein resulting from aberrant proteolytic processing of APP via β-secretase (SadighEteghad et al., 2015). A prior study demonstrated that bryostatin-1, through activation of
PKCε, attenuated Aβ plaque deposition by potentiating the secretion of a soluble, nontoxic form of APP α-secretase through a non-amyloidogenic pathway (Etcheberrigaray et
al., 2004; Hongpaisan, M-K Sun, et al., 2011) (Figure 2.2). Additionally, repeated
administration of bryostatin-1 (40 μg/kg; i.p.) in double transgenic AD mice reduced the
deposition of neurotoxic peptides- Aβ40 and Aβ42 with concomitant improvement in
survival and behavioral outcomes (Etcheberrigaray et al., 2004). Furthermore, bryostatin1 treatment stabilized and prolonged activity of neprilysin, a potent Aβ-degrading enzyme,
in the brain through upregulation HuD, an mRNA binding protein responsible for neural
development and neuronal plasticity (Lim and Alkon, 2014).
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Figure 2.2: Bryostatin-1 attenuated Aβ plaque deposition in Alzheimer’s disease in
a PKCε dependent pathway. AD pathophysiology is widely characterized by the
deposition β-amyloid peptide (Aβ) in the brain which ultimately results in
neurodegeneration and cognitive defects. The fate of amyloid precursor protein (APP)
cleavage by secretases (proteolytic enzymes) determines the severity of disease
progression. In, the amyloidogenic pathway, APP is sequentially cleaved by β- and γsecretase resulting in the generation of the neurotoxic Aβ plaques. Whereas in the nonamyloidogenic pathway, α-secretase cleaves the APP, generating soluble α-APP
fragments (sAPPα) and C-terminal fragment (C83), which is further cleaved by γsecretase, producing non-toxic P3 and APP intracellular domain (AICD). Evidence
suggest that PKC is instrumental in the processing APP. Activating protein kinase C
epsilon (PKCε) by bryostatin-1 is shown to enhance the α-processing of APP as indicated
by increased production of sAPPα while decreasing the formation of Aβ plaques in the
brain.
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Analysis of autopsy-confirmed AD brains revealed elevated levels of Aβ along with
reduced PKCɛ, manganese superoxide dismutase (MnSOD), and brain derived
neurotrophic factor (BDNF) in hippocampal CA1 pyramidal neurons (Sen et al., 2018).
The same association was noticed in in vitro using cultures of human primary
hippocampal neurons. These effects were reversed by bryostatin-1 administration. A
preclinical study using 8-month-old transgenic AD mice showed that bryostatin-1 (30
μg/kg; i.p) administration for 12 weeks restored the levels of PKCɛ with concomitant
decline in soluble amyloid beta protein levels (Hongpaisan, M-K Sun, et al., 2011). In
addition, the authors found that bryostatin-1 prevented the inhibition of BDNF levels
associated with synaptic loss even before the deposition of Aβ plaques in the
hippocampal neurons (Hongpaisan, M-K Sun, et al., 2011). Moreover, in vitro studies
showed that treatment with tert-butyl hydroperoxide (TBHP) induced increased reactive
oxygen species (ROS) while decreased the levels of PKCɛ, MnSOD, BDNF as well as
neuronal density (Sen et al., 2018). These effects were recused by bryostatin-1
administration (Sen et al., 2018). Studies showed that aging results in decreased
proteosome activity (Khan and Nelson, 2018), which plays a central role in degrading and
clearing Aβ plaques in the brain (Saez and Vilchez, 2014; Cao et al., 2019). However,
bryostatin-1 at sub-nanomolar to nanomolar concentrations (0.3-30 nM) enhanced
proteasomal activity in the ubiquitin-proteasome pathway in PKCɛ dependent manner
(Khan and Nelson, 2018). Taken together, bryostatin-1 improved neuronal survival and
reduced oxidative stress in the hippocampal neurons indicating attenuation of neuronal
dysfunction as seen in AD.
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PKC-mediated signaling pathways play significant roles in AD pathophysiology.
PKC activation mediates both excitatory and inhibitory synaptogenesis, which is vital for
the neuronal plasticity involved in memory and learning (Sun and Alkon, 2005;
Hongpaisan et al., 2013; Nelson et al., 2017). Bryostatin-1 administration (10 μg/kg; i.p.)
to young adult rats increased the density of mushroom spines, a PKC dependent longterm associative memory storage unit, on dendrites (Hongpaisan and Alkon, 2007). In
addition, bryostatin-1 treatment increased double-synapse presynaptic boutons that
synapse with mushroom spines, and pre-synaptic vesicles indicating enhanced memoryinduced synaptogenesis (Hongpaisan and Alkon, 2007). Bryostatin-1 induced
upregulation of mushroom spine synapses and BDNF release in apical dendrites of CA1
pyramidal neurons, which reversed age-dependent cognitive decline (Hongpaisan et al.,
2013). Furthermore, bryostatin-1 improved learning and memory by significantly
increasing the frequency and amplitude of GABAergic inhibitory postsynaptic currents as
well as increasing the firing rate of GABAergic interneurons, both of which indicate
enhanced neurotransmission in hippocampal neurons (Xu et al., 2014).
Acute oral administration of bryostatin-1 (5 μg/mouse in vehicle oil control) to
transgenic AD mice for less than two weeks significantly improved learning and memory
performance while reducing plaque deposition in the cortex/hippocampus when
compared to i.p administration (Schrott et al., 2015). Recently, a nanoparticleencapsulated bryostatin-1 formulation showed an increased efficacy when compared to
unmodified bryostatin-1 (Schrott et al., 2021). The study showed that AD transgenic mice
(6.5 to 8 months of age) treated with nanoparticle encapsulated bryostatin-1 formulation
(1, 2.5, or 5 μg/mouse) showed improvements in spatial memory on Morris water maze
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indicating the effectiveness of the novel nanoparticle-encapsulated formulations of the
drug in treating cognitive deficits associated with AD (Schrott et al., 2021).
The first clinical study of bryostatin-1 in AD patients was conducted by Nelson et
al., 2017. Bryostatin-1, administrated at a dose of 25μg/m2; i.v in a double blind Phase IIa
trial, showed improvement in Mini-Mental State Examination (MMSE) score between
treatment and placebo groups (Nelson et al., 2017). The data also showed that bryostatin1 was well tolerated in AD patients (Nelson et al., 2017). Following the favorable
pharmacokinetic profile of bryostatin-1 from Phase IIa trials and promising results from
compassionate use trials, a double-blind, randomized, placebo-controlled Phase II trial to
investigate the safety, tolerability, and efficacy of bryostatin-1 in advanced AD patients
was conducted (Farlow et al., 2019). Although there was no significant difference in the
prime outcome between the placebo and treated groups, the study provided a dose limit
for future clinical trials as <40μg (which corresponds approximately to < 25μg/m2 doses).
In addition, the authors suggested that memantine, a conventional medication used to
treat moderate-to-severe Alzheimer's disease, blocked bryostatin-1 induced potential
therapeutic effects (i.e., decrease in Severe Impairment Battery (SIB) scores in AD
patients). Future trials should focus on testing the efficacy of bryostatin-1 at 20μg in the
treatment of moderate to severe AD in the absence of memantine thus preventing any
compounding factors (Farlow et al., 2019).
BRYOSTATIN-1 IN TBI
The incidence of TBI in the US is estimated to be 1.7 million incidents per year and
occurs mainly among adolescents (15-19 years) and older populations (>65 years) (Alan
Georges; James G. Booker, 2019). However, it imposes significant problem in older
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patients with increased emergency department visits, hospitalizations, and mortality
(Thompson et al., 2006; Gardner et al., 2018; Peters and Gardner, 2018). Most TBIs are
classified as mild and are mainly caused by closed brain injuries such as a concussion
resulting from a car or sports accident or a fall (Alan Georges; James G. Booker, 2019).
In case of older individuals, falls are considered to the primary mechanism of TBI affecting
more women than men (Peters and Gardner, 2018). Age-related increased prevalence of
co-morbidities, pre-existing health conditions, consumption of certain drugs such as
warfarin along with intracranial changes such as dura adherence to skull, cerebrovascular
atherosclerosis and bridging vein fragility are some factors that associated with increased
disease severity and higher rate of mortality as seen in older adults (Thompson et al.,
2006). The pathophysiology of TBI is complex resulting from primary impact and
secondary injuries, both of which can exacerbate cerebral damage. The underlying
mechanism(s) involve activation of various biochemical and molecular pathways resulting
in neural depolarization, ionic disturbances, glutamate excitotoxicity, mitochondrial
dysfunction, increased oxidative stress, inflammatory response and neuronal death
(Kinoshita, 2016; Galgano et al., 2017). Disruption of the BBB may worsen the injury by
increasing cerebral edema and intracranial pressure and reducing cerebral perfusion
pressure (Kinoshita, 2016; Galgano et al., 2017). Additionally, aging can negatively
impact the outcomes following TBI (Thompson et al., 2006). Without proper interventions,
these consequences can lead to permanent brain injury and a higher predisposition to
worsened outcomes following a repeated head injury (Dewan et al., 2018).
Experimental studies demonstrate that shockwave-induced TBI disrupts the BBB
and increases deposition of Aβ as a consequence of secondary damage (Itoh et al., 2009;
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Abdul-Muneer et al., 2013; Hue et al., 2014). Administration of bryostatin-1 (2.5 mg/kg;
i.p) to young adult male Sprague-Dawley rats 5 mins after shockwave-induced TBI
significantly reduced BBB permeability by upregulating expression of the tight junction
proteins, zonula occludens-1 (ZO-1), occludin, and VE-cadherin (Lucke-Wold, Logsdon,
et al., 2015). In addition, bryostatin-1 was able to decrease toxic PKCα protein levels
while increasing PKCε expression levels in isolated cerebral microvessels, thereby
maintaining the integrity of BBB after injury (Lucke-Wold, Logsdon, et al., 2015).
Furthermore, extended treatment of bryostatin-1 starting at 8h following mild TBI (mTBI)
over 2 weeks protected the brain from synaptic loss and cognitive decline in male C57b6/J
mice (Zohar et al., 2011). This rescue was possibly mediated through bryostatin-1 binding
to the regulatory domain of PKC (Kortmansky and Schwartz, 2003) to increase ADAM10
(putative α-secretase) levels while decreasing BACE-1 (β-secretase) levels. Altering the
expression of both ADAM10 and BACE-1 would ultimately lower the rate of Aβ deposition
leading to reduced plaque formation and possibly enhanced memory and cognition
(Zohar et al., 2011). This study also indicated that repeated application of bryostatin-1
rescued the TBI-induced reduction in pre and post synaptic neural connections in the CA1
region of the hippocampus (Zohar et al., 2011). Taken together, bryostatin-1 is a potential
treatment for both short and long term TBI sequelae. However, these protective effects
are not observed when bryostatin-1 is administrated at sub-acute time points such as 14
days post injury (Zohar et al., 2011). Identifying the appropriate therapeutic window of
bryostatin-1 for maximum neuroprotective effect following brain injury is warranted. Future
studies should investigate the effect of co-treatment of bryostatin-1 and current treatment
strategies for TBI.
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BRYOSTATIN-1 IN AIS
AIS is a disease of the elderly. In the US, it is the fifth leading cause of death and
major cause of adult disability (Yang et al., 2017). About 75% of the strokes occur in
patients above 65 years (Yousufuddin and Young, 2019). As the number of aged
population (>65 years) is expected to rise, there is increased prevalence of hypertension,
diabetes, obesity, and cardiovascular diseases coupled with lifestyle changes that
significantly contributes to the growing incidence of stroke in aging population (Kowalska
et al., 2017). It is estimated that the incidence of stroke will double over the next 40 years
(2010–2050) affecting the elderly (aged ≥75 years) and minority groups (Benjamin et al.,
2018). Elderly patients (>85years) are associated with longer hospitalization and thereby
increase the burden on healthcare system (Benjamin et al., 2018). Especially in this age
group (>85 years), women are prone to increased stroke mortality and disability than men
due to increased life span for women (Rexrode et al., 2022). So far, reperfusion with
tissue plasminogen activator (tPA) has been the gold standard to treat patients suffering
from ischemic stroke but the treatment has a narrow therapeutic widow requiring
administration of tPA within 3-4.5 h after onset of stroke (Peña et al., 2017). Moreover,
not all AIS patients are eligible for tPA treatment due to tPA associated intracerebral
bleeding and risk of hemorrhagic transformation (HT) (Peña et al., 2017). These
shortcomings emphasize the need for developing novel pharmacological agents that act
as adjuvants with the existing therapy to prolong the therapeutic window and efficacy of
tPA by reducing its adverse effects.
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Studies indicate that co-administration of bryostatin-1 with tPA exhibited
neuroprotective effects following ischemic stroke (Tan et al., 2013, 2015). Administration
of tPA (5 mg/kg; i.v.) adjuvated with bryostatin-1 (2.5 ug/kg; i.v.) every third day over a
three-week course demonstrated enhanced survival rates and reduced brain swelling in
aged female Sprague-Dawley rats with experimentally induced ischemic stroke (Tan et
al., 2013). Furthermore, bryostatin-1 treatment not only extended the time window for tPA
administration to 6 h post stroke, but also reduced mortality, hemispheric swelling and
tPA induced-HT (Tan et al., 2015). Bryostatin-1 at nanomolar concentrations prevented
degradation of the active, membrane-bound PKC enzymes (Sun et al., 2008). Tan and
coworkers demonstrated that bryostatin-1 through PKC activation prevented BBB
disruption via downregulation of matrix metalloproteinases-9 (MMP-9) (Tan et al., 2015).
In addition, the authors showed that bryostatin-1 differentially regulated the expression of
PKC isozymes predominantly present in the brain following ischemic stroke (Tan et al.,
2015). Bryostatin-1 initially caused upregulation of PKCα and PKCɛ; however, at 24 h
post-stroke the expression of PKCα was downregulated while PKCɛ expression levels
remained elevated (Tan et al., 2013).
Post-ischemic chronic administration of bryostatin-1 in rats rescued ischemia
induced spatial learning and memory impairment but not sensorimotor ability in a PKC
dependent fashion (Sun et al., 2008). In addition, impaired rats that were administered
bryostatin-1 following AIS displayed retrieved learned spatial experiences i.e. pretrained
water maze (Sun et al., 2009). Moreover, bryostatin-1 treatment was able to induce
neurotrophic factors (such as BDNF) and synaptogenesis while preventing neuronal loss,
loss of dendritic spines and presynaptic vesicles in pyramidal neurons of rat hippocampus
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(Sun et al., 2008, 2009). In combination with voluntary exercise, bryostatin-1 was shown
to improve functional recovery after cerebral infarct in male Sprague-Dawley rats
(Mizutani et al., 2015, 2016). Bryostatin-1 in adjuvant with exercise increased
phosphorylation of α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
(AMPAR) subunit GluR1 at the serine-831 residue in the perilesional cortex, which is
essential for neuronal plasticity through long-term potentiation (Mizutani et al., 2015). In
addition, the treatment of bryostatin-1 and exercise showed increased levels of serotonin
(5-HT), an important neurotransmitter involved in synaptic plasticity (Lesch and Waider,
2012), and decreased 5-HT turnover in the perilesional cortex indicating a positive
correlation between serotonin dynamics and motor performance (Mizutani et al., 2016).

BRYOSTATIN-1 IN MS
MS is a progressive, autoimmune disorder that leads to progressive degeneration
of myelinated neurons in the CNS (Oh et al., 2018). Initially, MS was considered a disease
of the young adults with a typical disease onset between 20-40 years (Shirani et al.,
2015). However, data from recent reports showed a significant increase in the mean age
of onset, with a notably higher incidence observed in patients over 60 (Solaro et al., 2015;
Koch-Henriksen et al., 2018). This is associated with severe disability (Confavreux and
Vukusic, 2006) as well as higher risk of losing all income from earnings thereby
exacerbating the socioeconomic status of MS patients (Wandall-Holm et al., 2022). MS
is characterized by neuroinflammation followed by deposition of CNS plaques that are
comprised of debris from immune cells, demyelinated axons, axonal injury and glial scar
tissue that ultimately results in neuronal dysfunction (Ghasemi et al., 2017). The initial
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relapse-remitting phase of MS is mediated by the migration of autoreactive T-cells,
specifically Th1 cells, across the BBB into the CNS leading to demyelination followed by
progressive secondary axonal death (Losy, 2013). Age-related mechanisms such as
immunosenescence may accelerate this transition from acute multifocal recurrent
inflammation to diffuse chronic neurodegeneration (Confavreux and Vukusic, 2006;
Musella et al., 2018; Vaughn et al., 2019; Ostolaza Ibáñez et al., 2022). The existing
treatment options for MS do not focus on preventing disease progression related disability
as seen in the case of elderly (Vaughn et al., 2019) resulting in increased proportion of
older patients not receiving treatment for MS (Wandall-Holm et al., 2022). This imposes
a significant challenge on the elderly.
Bryostatin-1 has been shown to be a promising lead drug for MS based on its
immune-potentiating properties (Ariza et al., 2011; Safaeinejad et al., 2018). In vitro
studies indicated that bryostatin-1 was capable of facilitating the switch from Th1 to Th2
mediated immune responses by acting like a toll-like receptor 4 (TLR-4) ligand and
stimulating the release of anti-inflammatory cytokines (Ariza et al., 2011). Emerging
evidence showed that bryostatin-1 (30 μg/kg) administered 3 d per week had beneficial
therapeutic effects on MS complications in a mouse model of experimental autoimmune
encephalomyelitis (EAE) (Kornberg et al., 2018). This study showed that upon bryostatin1 treatment with concurrent EAE induction in mice, there was a diminished peripheral
immune response and decreased lymphocyte infiltration into the brain with significant
reductions in total CD4+ and Th1 lymphocyte populations (Kornberg et al., 2018).
Although dynamic changes in BBB permeability were not measured in these studies, it
stands to reason based of the effects of bryostatin-1 on BBB integrity in other neurological
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injury models (Tan et al., 2013, 2015; Lucke-Wold, Logsdon, et al., 2015) that the
beneficial effects of bryostatin-1 noted in these studies were due, at least in part, by
reducing the degree of BBB compromise following induction of EAE in mice.
In addition, bryostatin-1 administration was shown to modulate antigen
presentation of dendritic cells (DCs) through upregulation of CD86 but not CD40, another
costimulatory protein expressed on antigen presenting cells (APCs) that is needed for T
cell activation (Kornberg et al., 2018). Another possible mode for the pharmacological
action could be demonstrated by the ability of bryostatin-1, at low doses, being able to
upregulate IL-10, an anti-inflammatory cytokine and arginase-1, a classic M2a
macrophage marker, both of which are indicative of wound healing and tissue repair in
the CNS (Kornberg et al., 2018). In addition to macrophages and DCs, future studies
should focus on the immunologic actions of bryostatin-1 on microglia, the prominent
immune cells of the central nervous system (CNS). Understanding the detailed molecular
mechanism underlying the immunologic actions of bryostatin-1 in multiple sclerosis model
is warranted.

BRYOSTATIN-1 IN NEUROAIDS
HIV infects various cells of the body causing acquired immunodeficiency syndrome
(AIDS). It is well known that HIV-1 crosses the BBB leading to HIV-associated
neurocognitive disorders (HAND) such as HIV-associated dementia, neuroAIDS and
opportunistic CNS infections (Eisfeld et al., 2013). Owing to the effectiveness of
antiretroviral therapies, the number of aged individuals (45 years and above) living with
HIV infection has increased to 50% in the high income countries like US (Collaboration,
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2008; Cohen et al., 2015). However, response to antiretroviral treatment is different
between young and aged cohorts with aged patients showing reduced immune recovery
possibly due to age-related immunosenescence (Mpondo, 2016). Older patients are at
higher risk of mortality due to HIV (Jiang et al., 2013). Additionally, the prevalence of HIVassociated neurocognitive disorders may be accelerated by the person’s age (especially
above 50 years) (Mackiewicz et al., 2019). Recent reports have demonstrated the
association of apolipoprotein E (ApoE) in the pathogenesis of HAND along with increased
secretion of the beta-amyloid peptide and presence of amyloid plaques in the brains of
HIV positive patients (Geffin and McCarthy, 2018; Fulop et al., 2019; Mackiewicz et al.,
2019). These studies further strengthen the hypothesis that aged individuals bearing HIV
infection are increasingly susceptible to developing AD and other AD-related dementias
(Fulop et al., 2019; Mackiewicz et al., 2019). Given the importance of influence of age on
HIV disease progression (Jiang et al., 2013), it would be important to identify therapeutic
agents targeting novel mechanisms underlying the pathogenesis of age-related HIV
neurodegeneration (Mackiewicz et al., 2019).
Although, combination antiretroviral therapy (cART) can efficiently control the virus
to almost undetectable systemic levels, cART has been unable to completely eradicate
HIV from the body due to viral sequestration and rebound stores, such as occurs in CNS
reservoirs (Eisfeld et al., 2013; Dahabieh et al., 2015). CNS-derived HIV viral strains have
unique features when compared to those found in peripheral compartments that
differentially modulate viral replication, latency and resistance to drugs, such as latency
reversal agents (LRA) (L. R. Gray et al., 2016; Lachlan R. Gray et al., 2016). This
difference in response poses a significant limitation for the body’s ability to eradicate brain
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reservoirs of HIV. Thus, an urgent need exists to develop strategies to purge CNS viral
reservoirs.
In the CNS, microglia and astrocytes are major sites for HIV replication and
sequestration (Marban et al., 2016). Studies indicate that administration of bryostatin-1
reduces viral load by improving the induction of latent HIV to enhance effectiveness of
cART (Marsden et al., 2017, 2018). Bryostatin-1 functioned in synergy with several LRAs,
including histone deacetylase inhibitors, bromodomain inhibitors (BETi) and polyanionic
carbosilane dendrimers, to fAIS (Perez et al., 2010; Higashida et al., 2011; Darcis et al.,
2015; Albert et al., 2017; Heffern et al., 2019; Relaño-Rodríguez et al., 2019; Peng et al.,
2020). When co-administered, bryostatin-1 and JQ1 (BETi) exhibited a highly efficient,
synergistic activity for HIV reactivation in latently infected microglial cells in vitro (Darcis
et al., 2015). The mechanism for this synergistic activity of bryostatin-1 was found to be
mediated through increased PKCα and PKCδ activities, which is indicative of the need
for higher doses (Díaz et al., 2015). From a therapeutic perspective, this finding is
troubling as higher doses of bryostatin-1 have been shown to lead to astrogliosis,
disturbances in astrocytic glutamate uptake/release balance, chronic neuroinflammation
and increased neuronal excitotoxicity (Proust et al., 2017). Furthermore, higher doses of
bryostatin-1 have been shown to increase BBB permeability by upregulating the
expression of pro-inflammatory cytokines (Dental et al., 2017). A prior study found this
pro-inflammatory activity of bryostatin-1 could be attenuated by co-administration of JQ1
but no other LRAs (SAHA and BIX-01294) (Proust et al., 2017). Therefore, it is important
to carefully evaluate the choice of LRA in combination with bryostatin-1 to mitigate the
potential risk of neurotoxicity associated with bryostatin-1. Future studies should also
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focus on developing multifunctional nano therapies comprising antiretroviral drugs (ARV)
and LRAs to overcome problems associated with HIV latency in the CNS and aid in
targeted drug adherence (Jayant et al., 2018).

DISCUSSION
To ensure maximum pharmacological effect, it is important to understand the
pharmacokinetics of bryostatin-1 as well as its exposure time and concentrationdependent effects on various PKC isozymes. Up until early 2000s, there was not an
established method to reliably quantify the levels of bryostatin-1 in human plasma which
ultimately hindered the progress of bryostatin-1 research in cancer treatment (Blackhall
et al., 2001). Over the decades, several quantitative methods have been developed to
measure bryostatin-1 levels in with high sensitivity. In 2005, Zhao et al., developed a
novel assay using triple quadrupole mass spectrometer to measure bryostatin-1 in human
plasma sample with a detection limit of 50pg/ml. In this study, bryostatin-1 was
administered over 2 weeks as continuous intravenous infusion at a single dose level of
20 ug/m2 and the half-life of the drug was found to be 9 h (Zhao et al., 2005). Recently,
Nelson and colleagues demonstrated that bryostatin-1 detection limit can be improved by
adduct formation by adding sodium acetate (Nelson et al., 2014). They developed an
ultrasensitive mass spectrometric method detecting bryostatin-1 sodium adducts at low
pmol/l concentrations and enabled measurement in brain and other tissues without the
use of radioactive labels (Nelson et al., 2014). It is known that bryostatin-1 is relatively
stable in vivo, widely distributed but predominately present in lung, liver, gastrointestinal
tract, and fatty tissue (Sun and Alkon, 2006). It has also been shown to cross the blood
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brain barrier in mice following iv administration despite being a large molecule (MW =
905.03 g/mol) (Nelson et al., 2014). The study showed that brain uptake is saturated at
doses of 10μg/m2 and the maximum brain concentration (Cmax) of bryostatin-1 was
0.20nM (Nelson et al., 2014). The plasma disappearance curve of bryostatin-1 is fitted
into one compartment model for i.p. administration and into a two-compartment
pharmacokinetic model for i.v. administration (Sun and Alkon, 2006; Nelson et al., 2014,
2017). A single dose (25 μg/m2) of bryostatin-1 showed maximum levels of bryostatin-1
and its target PKCɛ within 1 h after the onset of infusion (Nelson et al., 2017) with rapid
elimination rate (22.97h and 28.76h for i.v. and i.p. administration respectively) (Sun and
Alkon, 2006). In addition, pharmacokinetic profiles demonstrated increased plasma drug
concentration upon repeated and continuous infusions of bryostatin-1 (Zhao et al., 2005),
indicating accumulation of the drug possibly due to decreased elimination rate constant
(0.027 min-1) while increased elimination half-life (32-200h) (Nelson et al., 2017). This
prolonged exposure of bryostatin-1 is due to enterohepatic circulation as the drug is
present in higher concentrations in the liver and gastrointestinal tract and cleared initially
(within 12h) through urine and later (within 72h) through urine and feces (Sun and Alkon,
2006).
One main reason for the failure of bryostatin-1 as a chemotherapeutic agent is
because PKC isoenzymes are involved in both oncogene and tumor suppressor gene
activation (Garg et al., 2013) and the variable expression of PKC isozymes in different
types of tumor (Isakov, 2018) affects the efficacy of bryostatin-1. Administration of
bryostatin-1 may only be effective when treating tumors harboring a specific PKC
isoenzyme profile (Blackhall et al., 2001). Despite the differences in pathology, various
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age-related CNS disorders share some degree of similarity in PKC dependent
mechanisms (Sun and Alkon, 2006; Lucke-Wold, Turner, et al., 2015). Preclinical studies
showed that bryostatin-1 crosses the BBB and specifically activates brain PKCɛ (Nelson
et al., 2014). PKCɛ is a promising biomarker of AD (Khan et al., 2015). Research showed
that PKCɛ levels in skin fibroblasts could serve as potential evaluation tools for the
detection of early AD by reflecting changes in brain PKCɛ levels (Khan et al., 2015).
Investigating the use of other PKC isozymes as peripheral biomarkers for the diagnosis
and prognostication of neurological diseases is warranted.
The exact mechanism of action of bryostatin-1 is unclear. Bryostatin-1 has been
shown to induce biphasic effects on PKC activity (Nelson et al., 2017; Ly et al., 2020). At
low concentration (<30μg/m2), bryostatin-1 leads to PKC translocation from the cytosol
to the membrane, which is a measure of its activation. This is followed by a brief period
of downregulation characterized by ubiquitination of PKC and degradation by
proteasomal machinery (Sun and Alkon, 2006). A previous study showed that low doses
of Bryostatin-1 (0.1-0.25 ng/ml) with short exposure times, resulted in PKCɛ induced
prolonged protein synthesis necessary for long-term memory in a mollusc Hermissenda
model (Alkon et al., 2005). The authors showed that this prolonged protein synthesis
lasting for at least one week is due to bryostatin-1 induced PKCɛ activation, followed
initially by down-regulation and then de novo synthesis of PKC (Alkon et al., 2005). Thus,
PKC modulators can produce long-term changes even after complete elimination of the
drug from the system (Nelson et al., 2017). More recently, mammalian unc13 isoform 1
(Munc13-1), a C1 domain-containing protein which shares activators with novel and
conventional PKC isoforms, has high binding affinity (Ki of 0.45 ± 0.04 nM) for bryostatin-
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1and is identified as a molecular target in vitro (Blanco et al., 2019). Thus future studies
should investigate other neuronal signaling targets of bryostatin-1 such as munc 13,
chimaerins and RasGRPs along with that of PKCs (Blanco et al., 2019).
Majority of the oncology clinical trials administered IV infusions of bryostatin-1 at
high doses (>30ug/m2) or over long periods of time (Nelson et al., 2017). Although,
bryostatin-1 showed promising anti-neoplastic activity in rodent models of cancer, it failed
to progress beyond Phase I/II clinical trials (Kollár et al., 2014). Increased drug
concentration and/or prolonged exposure resulted in the halt of the clinical trials due to
adverse effects, most notably myalgia and cancer progression (Kollár et al., 2014; Farlow
et al., 2019). Some of the toxicities associated with bryostatin-1 administration include but
not limited to phlebitis, lymphopenia, infection without neutropenia, hypophosphatemia,
seizure, hypotension, diarrhea, and dehydration (Blackhall et al., 2001; Kollár et al.,
2014). The exposure of bryostatin-1 is critical in designing its mechanism of action in
neurological disorders (Table 2.1). At higher doses of bryostatin-1, the brain drug
concentration is saturated (Nelson et al., 2014). Sub-optimal concentrations are well
tolerated by the body (Nelson et al., 2017; Farlow et al., 2019). Phase II clinical trial in AD
patients demonstrated the dose limit of bryostatin-1 to be 40μg (25 μg/m2) (Farlow et al.,
2019). Recently Cogram et al showed that chronic treatment (13 weeks) of bryostatin-1
(20 µg/m2, i.v., 2 doses/week) resulted in significant therapeutic effects along with no
evidence of adverse effects in a mouse model of fragile X syndrome (Cogram et al.,
2020).
Owing to its short half-life and rapid elimination rate from plasma after single bolus
dose (Lucke-Wold, Turner, et al., 2015), low dose continuous infusions over extended
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period is necessary for improved efficacy (Nelson et al., 2017; Farlow et al., 2019).
However, continuous IV infusions can be painful and lead to phlebitis and adverse
reactions at the site of infusions (Blackhall et al., 2001; Kollár et al., 2014; Farlow et al.,
2019). This could be overcome by acute oral administration of bryostatin-1 (Schrott et al.,
2015). The authors showed that gavaged bryostatin-1 is not metabolized by liver enzymes
as evidenced by in vitro absorption, distribution, metabolism and excretion (ADME)
studies using human hepatocyte cells, and produced superior efficacy and significant
functional outcomes compared to the intraperitoneal administration in a rodent model of
AD (Schrott et al., 2015). Pharmacokinetic analysis revealed that <5% of bryostatin-1 is
taken up in the circulation when administered orally suggesting that lower concentrations
of bryostatin-1 are sufficient to induce a therapeutic effect in vivo (Schrott et al., 2015).
Understanding the minimum blood/brain drug concentration required to produce
neuroprotection is warranted. Furthermore, the authors developed a hydrophilic
nanoparticle formulation of bryostatin-1 that increased its bioavailability and
demonstrated enhanced PKC-ε and PKC- δ activity along with improved cognitive scores
in a rodent AD model (Schrott et al., 2020). Future studies should focus on developing
newer formulations as well as optimizing the route of administration and the dosing
strategy to maximize the therapeutic benefits of bryostatin-1 to treat neurological
disorders.

CONCLUSION
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Accumulating evidence from cellular and animal models demonstrates that the
neuroprotective effects of bryostatin-1 is exerted by pharmacological modulation of
various PKC isozymes (Sun and Alkon, 2006). Since PKC signaling plays a crucial role
in several CNS related diseases (Battaini, 2001), bryostatin-1 is indeed an attractive
candidate in the treatment of several neurological injuries/diseases including but not
limited to AD, TBI, ischemic stroke, MS and neuroAIDS. Bryostatin-1 is currently being
investigated in several Phase I and II clinical trials, assessing the safety, tolerability, and
long-term efficacy profiles in the treatment of AD and as a LRA in HIV infected patients
(Gutiérrez et al., 2016; Nelson et al., 2017; Farlow et al., 2019) (Table 2.2). Recently,
bryostatin-1 received organ drug status by the FDA as a possible treatment for Fragile X
syndrome (Cogram et al., 2020; Raghuvanshi and Bharate, 2020). So far it has
demonstrated favorable safety profile at low doses in humans (Sun and Alkon, 2006) and
has the potential to advance to Phase III trials as CNS therapeutic agent, alone or in
combination with other neuroprotective agents.

FUTURE STUDIES
Despite being an important lead candidate, the advancement of bryostatin-1 has
been hindered by an inability to scale up extraction to meet clinical demand. While a
scalable synthesis of bryostatin-1 has been reported, a more promising approach has
been the development of novel analogs, known as bryologs (Wender and Baryza, 2005;
Wender et al., 2005, 2006; Wender and Reuber, 2011). The bryologs have allowed for
customization based on type of therapeutic intervention sought and to limit off target
effects while retaining the same pharmacophoric functionalities of naturally occurring
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bryostatins (Staveness et al., 2016; Marsden et al., 2018). In a nutshell, bryostatin-1 and
its analogs hold significant promise for treating CNS diseases and also provide hope for
enhancing targeted therapy.
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Table 2.1: Bryostatin-1 doses tested in rodent model of neurological diseases/disorders
Disease
model
AD mouse
model

TBI rodent
model

Cerebral
ischemia
rat model

Dose regimen

Route of
administration

30 μg/kg
2 doses/week for 12
weeks

i.p.

40 μg/kg
3/week from 3 weeks6 months
25 μg/m2 - weekly;
15 and 20 μg/m22/weekly

i.p.

0.5, 1, 5 μg/mouse

Oral; i.p.

1, 2.5, 5 μg/mouse
nanoparticle
encapsulated
formulation; 3/week
before testing and
then daily for 5 days
30 μg/kg injection
followed by
5× injections over a
period of 14 days

oral

Treatment outcome

Reference

Prevents loss of hippocampal
synapses and the memory
impairment; reduces Aβ
plaques
Reduces Aβ plaques and
mortality rates

(Hongpaisan, MK
Sun, et al., 2011;
Sen et al., 2018)

Increases BDNF

(Nelson et al., 2017)

Activation of αsecretase and
PKC isoforms
Activation of αsecretase and
PKC isoforms

Improves learning deficits;
reduces plaque burden dose
dependently
Improves cognitive deficits

(Schrott et al.,
2015)

i.p

ADAM10
activation and
BACE1
deactivation

Protects against the cognitive
and synaptic pathologies

(Zohar et al., 2011)

2.5 μg/kg

i.p.

Increased PKCε
and decreased
PKCα

Decreases BBB breakdown

(Lucke-Wold,
Logsdon, et al.,
2015)

20 μg/kg
repeated dosing

i.p.

Activation of
PKCε

Improves cellular as well as
motor and cognitive behavior
outcomes

(Giarratana et al.,
2020)

2.5 μg/kg at 6h
+rtPA at 2h post
stroke;
doses every 3 days for
a total of 7 doses over
21 days
2.5 μg/kg at 2h
+rtPa at 6h post stroke

i.v. (tail vein)

Increased PKCε

(Tan et al., 2013)

i.p.

15 μg/m2
2 doses/week for 10
doses
15 μg/m2
2 doses/week
for 10 doses

i.v. (tail vein)

Increased PKCε
and decreased
MMP-9
PKC dependent

Increases survival, reduces
infarct volume, decreases
hemispheric
swelling/atrophyand
improves neurological
function
Ameliorates BBB disruption
and reduces the risk of HT

(Sun et al., 2008)

i.v. (tail vein)

PKC-mediated

Antiapoptosis,
synaptogenesis, and
spinogenesis
Enhances neurotrophic
activity, induces
synaptogenesis, and
preserves spatial learning and
memory

i.v.

Mechanism of
action
Activation of
PKC isoforms
(α and ε)
Activation of αsecretase and
PKC isoforms
Activation of
PKCε
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(Etcheberrigaray et
al., 2004)

(Schrott et al.,
2021)

(Tan et al., 2015)

(Sun et al., 2009)

Mouse
model of
EAE

20 μg/m2
Acute study: two
doses
Chronic study: 2
doses/week for 10
doses
15, 10, 7.5, and 5
μg/m2
+ exercise

i.v. (tail vein)

Possibly
through
increase in
BDNF

Reverses the increased
sensitivity and depressive
immobility
induced by cerebral ischemia

(Sun and Alkon,
2013)

i.v. (tail vein)

Improves exercise induced
functional recovery at 15 and
10 μg/m2

(Mizutani et al.,
2015)

10 μg/m2
At 5days after infarct
+exercise
30 μg/kg
dosed at
3 d/week

i.v. (tail vein)

Possibly
through
increase in pGluR1
Increased 5-HT
and decreased
5-HT turnover
Possibly
through the
modulation of
TLR-4

Improves ischemia induced
motor dysfunction

(Mizutani et al.,
2016)

Promotes anti-inflammatory
phenotype on innate myeloid
cells and reverses neurologic
deficits

(Kornberg et al.,
2018)

i.p.

Table 2.2: Bryostatin-1 doses tested in CNS clinical trials
Disease model

Doses tested

PKC activation

Peak time

Peak
conc. in
plasma

Outcomes

HIV_
phase I

10 and 20
μg/m2
single doses,
infusion over
one hour

failed to activate
PKC

0.5-h after
infusion and
gradually
decayed in the
first 8 h

under 1
nmol/l

Safe and well
tolerated

(Gutiérrez et al.,
2016)
(NCT02269605)

AD_ doubleblind Phase IIa

25 μg/m2
single doses,
infusion over
one hour

Within 1-2h
after infusion

1ng/ml

Safe and well
tolerated;
increases MMSE
score at 3 h after
the end of infusion

(Nelson et al.,
2017)
(NCT02221947)

AD_
Randomized,
Double-Blind,
PlaceboControlled,
Phase II

20 μg and 40
μg, infusion
over a period
of 12 weeks

increased PBMC
PKCɛ levels at 1 h
followed by
long-term
downregulation
12-72h
-

-

-

40ug- adverse
effects with no
efficacy and
increased
dropouts.

(Farlow et al.,
2019)
(NCT02431468)

20ug- same
adverse effects as
that of placebo;
SIB scores showed
benefits from
baseline at week
15
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CHAPTER THREE

Characterization of age-related changes on cerebrovascular
topology in Sprague Dawley rats
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ABSTRACT
Aging-related anatomical and physiological changes have been implicated in the
pathogenesis of many neurological diseases, including Alzheimer’s and Parkinson’s
diseases and ischemic stroke. Altered function of reliable homeostatic pathways for
glucose control, energy metabolism, cellular replication and repair have been found to
play important roles in the pathogenesis of many of these age-related diseases. Another
age-related finding has been the marked decrease in vessel density, which pose to be
the underlying factor for reduced cerebral blood flow, impaired bioenergetics and altered
cellular response found in aged rodents when compared to younger rodents. What
remains unknown is, at what level of vessels are these changes occurring and how does
this change in density relates to adequate perfusion of the brain in aged rodents. In the
present study, we seek to gain a better understanding of the age-related anatomical
changes in the surface vessels of the brain. Using young (3-4 months old) and aged (1820 months old) female Sprague-Dawley rats, we employed a vessel painting technique
to specifically label cerebral endothelium so that we could visualize these vessels using
fluorescent microscopy. From the images obtained we used a vessel counting software
to perform a series of measurements to detail the absolute number and complexity of the
vessel architecture. Using this method, we found that aged animals showed significant
loss in vascular components along with 50% increased lacunarity. In contrast, young
animals exhibited increased cortical branching, capillary number, and complexity.
Therefore, a detailed characterization of vascular architecture reiterates the importance
of age in selecting animal models of ischemic stroke, which may subsequently improve
therapeutic success rate.
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INTRODUCTION
The human brain is particularly susceptible to the effects of aging. Independent of
other risk factors, such as hypertension, atherosclerosis, and diabetes, a person’s
advancing age is the predominant risk factor for many debilitating diseases, including
Alzheimer’s and Parkinson’s diseases, other dementias, ischemic stroke and cancers
(Kowalska et al., 2017; Bland, 2018; Franceschi et al., 2018; Hou et al., 2019). Billions
of dollars have been spent in pursuit of treatments to improve the overall quality of life for
persons suffering from these diseases; yet, age-related diseases are among the most
difficult to treat with few effective treatments available (Kirkland, 2016).
Case in point is ischemic stroke, which over the past three decades has seen
numerous promising preclinical neuroprotectant drugs fail to translate into a single
clinically viable therapeutic approach (Fluri et al., 2015; Shi et al., 2018; Xiong et al., 2018;
Lee et al., 2021). Many reasons have been posited for this disconnect, including
differences in complexity of human brain versus lower species, appropriate
pharmacokinetic characterization of drug penetrance and delivery into the brain, lack of
clinically relevant time courses for drug administration, lack of polypharmacy approaches,
flawed

construction

of

clinical

trial

exclusion/inclusion

criteria

and

inherent

inconsistencies within animal models of cerebral ischemia (i.e. anesthetic used, occlusion
material, unnatural reperfusion profile, acute / chronic assessments of functional
recovery, disconnect between infarct size and functional recovery (Lapchak et al., 2013;
Shi et al., 2018; Xiong et al., 2018; R Ma et al., 2020; Lee et al., 2021). While these issues
are valid considerations and provide excellent means to improve the rigor of research
being conducted, none of these approaches broaches the physiological consequences of
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aging as being the single most predictive risk factor for prevalence and severity of
ischemic stroke. A glance through the preclinical stroke literature demonstrably shows
the majority of preclinical stroke studies used rodents under the age of 6 months, with
most being 3 to 4 months old and some being as young as only a few weeks old (Kahle
and Bix, 2012; Fluri et al., 2015; Jackson et al., 2017; Narayan et al., 2021).
In this study, we investigated anatomical and physiological differences between
young and aged female Sprague-Dawley rats in surface topology and complexity of
cerebral vessels with a focus on the right and left middle cerebral arteries. We
hypothesized that cerebral blood vessel length, diameter, branching, and network
complexity differ substantially between old and young rats. Preliminary results of the
computations performed on these models indicate that vasculature in older brains is less
complex, includes less branching, and contains shorter vessels with greater diameter
compared to vascular networks in the brains of young rats. The higher average vessel
diameter in older brains is likely a compensatory mechanism for the inadequate perfusion
of these smaller, less branched vessels. Given the importance of vascular structure to
ischemic stroke outcomes, these structural differences suggest that age is an important
factor when selecting animal models of ischemic stroke (Jackson et al., 2017).

MATERIALS and METHODS
Animal Care and Use Statement. All procedures involving animals were approved by
the West Virginia University Animal Care and Use Committee and abided by ARRIVE
guidelines. 20 female Sprague-Dawley rats (3-4 and 20-22 months old; Hilltop Animal
Laboratories; Scottdale, PA) were acquired and housed in the vivarium at the West
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Virginia University (WVU) Health Sciences Center animal facility with food and water
accessible ad libitum. Rats were acclimated upon arrival for at least 7 d prior to testing.
All procedures were performed by investigators blinded to the age of the rats. All
procedures involving animals were approved by the WVU Animal Care and Use
Committee.

Serial Vessel Perfusion. Rats were euthanized by cardiac perfusion of 150 ml of warmed
1X phosphate buffered saline (37C; pH 7.4) with heparin (0.02 mg/g body weight; SigmaAldrich; St. Louis, MO) and sodium nitroprusside (0.075 mg/g body weight; SigmaAldrich) for 15 min under deep anesthesia using 4% inhaled isoflurane (Patterson). Rats
were then perfused with 50 ml of 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine
perchlorate (DiI; Life Technologies; Carlsbad, CA) followed by 200 ml of 4%
paraformaldehyde (PFA; Sigma-Aldrich). Care was taken to ensure no air bubbles were
trapped within the perfusion system, during each perfusion and switching between
perfusates. A peristaltic pump was used to deliver perfusates at a rate of 5.2 ml/min into
the left ventricle of the heart using a 25G needle. After perfusion with 4% PFA, rats were
decapitated and brains carefully excised and post-fixed in 4% PFA overnight.

Image Acquisition & Vessel Measurements. Vessel painted brains were imaged using
a widefield fluorescence microscope Olympus MVX 10. Whole brains were imaged under
1x objective and dorsal, ventral, and lateral surface images were captured to document
labeling efficiency. The captured images were then analyzed using ImageJ software using
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quantitative tools to obtain measurement of the physical parameters of the cerebral
vessels.

Vessel Measurement. Basic morphometrics were performed using ImageJ (NIH,
Bethesda, MD) software. In brief, microscopic images were preprocessed in ImageJ tool
and then analyzed using the open-source software AngioTool® (National Institute of
Health, National Cancer Institute, Bethesda, MD, USA). AngioTool® is a user-friendly
software AngioTool® used to measure several morphological and spatial parameters.
Using this tool, we calculated the total brain area, total area covered by the vessels,
vessel density, number of vessels, vessel length, number of junctions, junction density,
and number of endpoints. We also calculated the fractal dimensions and lacunarity, which
are used to analyze structural complexity and heterogeneity of patterns, for each image
using FracLac plugin for ImageJ. Branch order information was calculated using the same
software. Middle cerebral artery was considered the primary branch and branches
stemming of the primary were noted as secondary and so on. Additionally, we performed
diameter analysis using Python with python script packages Tiffile and Scipy from the
open-source Anaconda Distribution.

Statistical Analysis. All measurements and analyses were performed without
knowledge of group. Data were reported as mean ± standard deviation (SD). For classical
angiographic features measured from surface cortical vessels, unpaired t -test was used
to determine statistical significance between aged versus young animals. All statistical
analyses were performed using Graph Pad Prism software.
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RESULTS
Global reduction of surface cortical vessels in aged brain. In order to visualize the
cerebral vascular network, we employed vessel painting technique using 1,1’ dioctadecyl3,3,3’,3’ tetramethylindocarbocyanine perchlorate (DiI), dye to successfully label the
endothelial cells of the surface cortical vessels in rats (Hughes et al., 2015). We imaged
the whole brains under Olympus MVX 10 widefield microscopy showing dorsal, ventral,
and lateral aspects of the brains (Figure 3.1). Using this technique, 66% of young and
78% of aged brains were successfully perfused as determined by uniform pink staining
with absence of any white/blanched patches. Upon visual inspection, we noticed densely
packed microvascular organization in young cortex while the microvasculature was
sparse and disorganized in the aged cortex (Figure 3.1). In addition, there was substantial
reduction in surface cortical vessel as well as anastomosis in the aged brain (Figure 3.1B)
as opposed to young brain (Figure 3.1A).

Age-related changes on the vascular architecture of the surface cortical vessels. It
is well known that aging has a profound effect on the cerebral vasculature. We first wanted
to characterize age-related changes on the basic morphological and spatial parameters
of the surface cortical vessel on the axial plane. Classical vessel measurement
parameters using AngioTool identified a marked difference in cortical vessel topology
between young and aged female rats. Figure 3.2 demonstrates that aged rats displayed
significant reductions in (i) total brain surface area (p=0.045; versus in young rats), (ii)
vessel surface area (p=0.001; versus in young rats) and (iii) vessel density (p=0.0001;
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versus in young rats). Comparison of vessels (Figure 3.2) between young and aged
showed that aged rats displayed vessels with significant reductions in (iv) junctions
(p=0.0003), (v) junction density (p=0.0004) and (vi) number of endpoints (p=0.003).
Furthermore, evaluation of vessel measurements (Figure 3.2) found a significant
difference between aged and young cerebral blood vessels in (vii) total vessel length
(p=0.008) and (viii) lacunarity (p=0.0007) but no difference in (ix) average vessel length
(p=0.1563).

Age-related changes on the vascular architecture of the Middle Cerebral Artery
(MCA). The middle cerebral artery is the major artery supplying oxygenated blood and
nutrients to frontal, parietal, temporal areas of the brain (Gao et al., 2022). MCA is
clinically significant as occlusion of the artery results in cerebral ischemia leading to infarct
and necrosis of brain parenchyma (Gao et al., 2022). Age is a non-modifiable risk factor
for cerebral ischemia (Yousufuddin and Young, 2019) and preclinical studies have
demonstrated severe stroke outcomes and reduced functional recovery following
experimental stroke in aged rodents as opposed to young rodents (Rosen et al., 2005;
DiNapoli et al., 2008; Manwani et al., 2011). Therefore, we wanted to perform
morphometric analysis on the left and right MCA in young and aged rats using the
AngioTool. Figure 3.3 demonstrates significant decrease in (i) total brain surface area
(p=0.025; p=0.0003) (ii) vessel surface area (p<0.0001; p<0.0001) and (iii) vessel density
(p<0.0001; p<0.0001) in both right and left MCA of aged rats when compared to young
rats. Analysis of both (right and left) MCA vessel metrics between young and aged
displayed significant reductions in (iv) junctions (p=0.0005; p=0.0025), (v) junction density
(p=0.0076; p=0.013) but not (vi) number of endpoints (p=0.3044; p=0.2596).
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Furthermore, evaluation of vascular parameters (Figure 3.3) of the right and left MCA
found a significant difference between aged and young cerebral blood vessels in (vii) total
vessel length (p=0.0006; p=0.0001) and (viii) lacunarity (p=0.0494; p=0.0048) but no
difference in (e) average vessel length (p=0.6194; p=0.4071).

Age-related decrease in vascular complexity. Next, we wanted to determine if the agerelated reduction in vessel length could be compensated by changes in vessel diameter.
The output skeleton image generated from AngioTool (Figure 3.3B) was fed into Python
to create a histogram of surface cortical vessel diameters of aged and young animals
(Figure 3.4A). We observed a significant reduction in the number of small diameter vessel
in the aged animals versus young animals. Aged animals displayed about 50% reduction
in vessels with diameters less than 40 μm and 80% reduction in vessels with diameters
less than 10 μm. However, no differences were observed for large diameter surface
cortical vessels (>90 μm) between young and aged animals (Figure 3.4A). Additionally,
we wanted to determine vascular complexity in aged and young animals by analysis the
branches arising from the MCA. Figure 3.4B demonstrated age-dependent decline in the
number of higher order branches stemming from the MCA indicating decreased
collaterals and anastomoses due to aging.

DISCUSSION
With greater understanding of the implications of cellular senescence on
physiological function and the identification of critical time periods of changes in cellular
signaling occurring at all levels, from gene expression to post-translational modification,
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there is mounting evidence that (1) aged brains handle stress and trauma vastly different
than younger brains, (2) this difference in response is not linear, and (3) the degree and
expectation of recovery from brain injury is different in the aged versus the young. Taking
these considerations into mind along with the lengthy list of caveats already associated
with preclinical stroke models, it is difficult to ascertain the long-term value of using
younger animals to explore the mechanisms of ischemic stroke progression and recovery.
In the present study, we performed morphometrics analysis of the cerebral
vasculature of healthy young and aged female Sprague Dawley rats. With the aid of
vessel painting technique, we found that aged rats have reduced surface cortical vessels.
We demonstrated age related reduction in total brain area, classical vessel parameters
and increased lacunarity in axial surface cortical vessels as well as the MCA. In addition,
we demonstrated an overall decrease in small diameter vessels in aged brains compared
to young brains. Finally, we observed an age dependent decline in higher branch orders
sprouting from the main MCA indicating reduced vascular complexity in case of aged
animals.
Several techniques have been developed to visualize the structure of brain
vasculature. These include injection of various compounds such as resins, gelatin, latex,
dyes, and fluorescently labelled substances into the circulation to stain the vessels and
quantify morphological parameters like vessel density, length, and branch points (LugoHernandez et al., 2017). However, some of the drawbacks associated are use of
expensive reagents, difficulty in perfusion, incomplete vascular filing, and vascular
leakage of the dye into brain tissue (Konno et al., 2017; Lugo-Hernandez et al., 2017).
Herein, we employed vessel painting technique with a lipophilic carbocyanine dye 1,1′-
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dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI), that binds selectively
to the lipid membranes via insertion of its alkyl chains and commonly used for tract tracing
in the brain (Hughes et al., 2015). Using this simple, and economical method, we were
able to successfully label 66% of young and 78% of aged cerebral surface arteries. This
method is a reliable way of visualizing the smallest vascular elements with high resolution
using fluorescent microscopy (Hughes et al., 2015).
The cerebral vasculature controls blood supply to the brain and is responsible for
the maintenance of microenvironment for proper neuronal function (Bogorad et al., 2019).
With advancing age, the brain cerebrovascular architecture undergoes several changes.
In the present study, we demonstrated global reduction in surface cortical vessels in the
aged animals when compared to young animals which is accordance to previous reports
(Jin, 2019). Indeed, age-related cerebral vessel loss has been reported across multiple
species (Schager and Brown, 2020). Characterization of surface cortical vessel
parameters showed significant age-dependent reduction in vessel area, vessel density,
and total vessel length. This finding is consistent with previous reports demonstrating age
associated decline in cerebral microvascular architecture (Sonntag et al., 1997; Xu et al.,
2017; Li et al., 2018; Bálint et al., 2019; Lowerison et al., 2022). This age-related vessel
loss could be due to vessel pruning that is not counterbalanced by formation of vessels
(Cudmore et al., 2017), and/or due to reduced levels of proangiogenic factors leading to
decreased angiogenesis (Sadoun and Reed, 2003). Additionally, aging is associated with
global decreases in blood flow velocity, cerebral perfusion and global increases in vessel
tortuosity (Xu et al., 2017; Li et al., 2018; Lowerison et al., 2022). Taken together, it can
be inferred that age-related decline in cerebral microvascular network can lead to
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impairment in vascular supply due to reduced cerebral blood flow (CBF). Furthermore,
brain micro vascular changes is associated with impaired neurovascular coupling (Lipecz
et al., 2019; Shaw et al., 2021), a process which largely depends on the underlying
vascular structure to match the energy demands of the activated neurons (Lecrux and
Hamel, 2011; Iadecola, 2017; Tarantini et al., 2017). Recent studies have shown link
between neurovascular dysfunction and cerebral blood flow with worse cognitive
performance (Tarantini et al., 2017; Toth et al., 2017; Rensma et al., 2020; Bracko et al.,
2021). These findings strengthen the association between microvascular changes
leading to compromised cerebral blood flow and age-related memory and cognitive
impairment.
With increasing age, our brain undergoes structural and functional changes. At 65
years, it is estimated that majority of the brain regions decrease in area by 1% to 5% over
a span of 7 years and this decline becomes steeper with advancing age (Sele et al.,
2021). Using a surface-based reconstruction approach, the average total surface area of
a human was found to be 1,692 ± 117 cm2 and the global reduction in total surface area
was measured to be 3.68 cm2/year (Lemaitre et al., 2012). Accordingly, we showed
significant reduction in total brain area of aged animals compared to young animals. Sele
et al., 2021 demonstrated a strong co-relation between changes in anatomical structures
with changes in cognitive scores and estimated sharp declines in cognitive performance
with increasing age (Sele et al., 2021). In addition, we showed age-dependent increase
in lacunarity, which is a measure of gaps in patterns (Karperien et al., 2011). This finding
is consistent with previous reports and highlights the importance of such a parameter in
predicting the diseases outcomes (disability accumulation) in chronic neurodegenerative
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diseases such as Multiple Sclerosis (MS) and in the diagnosis of cognitive impairment
(Karperien et al., 2011; Arthur et al., 2019; Roura et al., 2021). Taken together, changes
in surface cortical area and lacunarity can be used as a cortical biomarker of cognitive
healthy aging.
The middle cerebral artery is the primary artery supplying blood to the vast majority
of the brain and has significant clinical relevance (Gao et al., 2022). The MCA and its
cortical branches carry oxygenated blood and nutrients to areas such as primary motor
and somatosensory cortex, insular, auditory cortex, basal ganglia, internal capsule,
speech and language centers of the brains (Navarro-Orozco and Sánchez-Manso, 2021).
It is the most common blood vessel that is occluded by an embolus or thrombus in case
of ischemic stroke resulting in cerebral edema and neuronal apoptosis (Navarro-Orozco
and Sánchez-Manso, 2021). Understanding the age-related remodeling of cerebral
arteries and arterioles is important as it may aid in predicting the risk of cerebrovascular
diseases (Diaz-Otero et al., 2016). In the present study, we observed a significant agerelated reduction in morphometric measures such as vessel area, vessel density, vessel
length, number of junctions and junction density of both right and left MCA of the rat brain.
This is because of reduced cerebral arterial anastomoses occurring between the
branches (Sonntag et al., 1997). Aged animals showed decreased ratio of arteriolar
anastomoses to arterioles (1:6.6) compared to young animals (1:5) (Sonntag et al., 1997).
Additionally, we showed that aged brains have less complex vascular metrics as evidence
by reduced number of distal branches while no changes in the proximal vessels sprouting
from the main MCA. This is consistent with reports demonstrating more pronounced agerelated vessel loss owing to reduced perfusion in distal brain regions like somatosensory,
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motor and retrosplenial cortices in contrast to proximal brain regions like striatum and
thalamus (Schager and Brown, 2020). As the complexity of the MCA vascular network
decreases with aging, the role of individual vessels will be important in determining the
degree of perfusion after occlusion as in the case of cerebral ischemia.
The brain microvascular network consists of communicating arteries that loop to
form the Circle of Willis at the base of brain, giving rise to the anterior, middle, and
posterior cerebral arteries (Schaffer et al., 2006; Bogorad et al., 2019; Navarro-Orozco
and Sánchez-Manso, 2021). Pial or leptomeningeal collaterals are small diameter vessels
on the cortical surface that connect distal branches of the anterior cerebral artery (ACA)
and posterior cerebral artery (PCA) with distal branches of the middle cerebral artery
(MCA) (Liebeskind, 2003). These collaterals are clinically significant as they determine
the redistribution of blood flow to distal regions following an occlusion and define the
degree of ischemic insult (Schaffer et al., 2006). In the present study, we found about 50
% reduction in small diameter vessels (<40 μm) and about 80% decrease in vessels with
diameter <10 μm on the axial surface of aged brain compared to young brain. With
reduced tissue perfusion due to reduced small diameter vessels, regions supplied by the
MCA in aged animals may have less resilience to interruptions or changes in blood flow
leading to exacerbated ischemic damage than young animals (Faber et al., 2011; J Ma
et al., 2020a). In addition, aged rats showed significant impairment in collateral dynamics
leading to increased severity of collateral failure as opposed to young rats (J Ma et al.,
2020a). Therefore improving collateral circulation may aid as adjuvant therapy to
recanalization therapy (Cuccione et al., 2016; J Ma et al., 2020b).

55

Some drawbacks associated with this study is that the dye DiI preferentially labels
arteries, leaving out veins and venules (Hughes et al., 2015; Konno et al., 2017). In
addition, the hydrophobic dye can form aggregates during perfusion causing occlusion of
small diameter blood vessels resulting in some degree of heterogeneity in labelling and
not suitable for microvessels staining (Konno et al., 2017). Furthermore, DiI dissolves in
alcohol

making

this

technique

not

suitable

to

be

combined

with

other

immunohistochemical methods (Hughes et al., 2015). However, this method was chosen
as it provides a simple, cost-effective and efficient alternative to complex techniques such
as corrosion casting for analysis of vascular parameters (Hughes et al., 2015; Konno et
al., 2017). Another limitation of this study is the imaging depth was limited to surface
cortical vessels allowing us to perform two-dimensional analysis of the vascular
structures. To further investigate three-dimensional capillary network characteristics
within the deeper brain regions at high resolution, histological analyses combined with
light sheet microscopy is warranted. This study was conducted in female rats. The
rationale for using female animals is women have increased life span compared to men
and hence have increased risk of chronic cerebrovascular diseases (CVD) such as stroke
and Alzheimer’s (Alharbi et al., 2020; Kumar and McCullough, 2021). In addition, the
aging blood brain barrier (BBB) of females shows ultrastructural modifications that might
contribute to altered capillary blood flow thereby contributing to vascular diseases (FríasAnaya et al., 2021). Sex hormones such as estrogens, progestins, and androgens have
shown to regulate vascular functions by acting on the cerebral vasculature (Robison et
al., 2019). A recent study demonstrated sex differences on the intrinsic structure of rat
MCA (Wang et al., 2020) possibly altering neurovascular coupling responses and
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cognition with aging. Therefore, understanding the structural characteristics of vessels in
young and aged male animals and its causative role in CVD will be useful in developing
therapeutic interventions for pre-clinical studies in the future.

CONCLUSION
In summary, we have systematically investigated age-related changes in surface
cortical vessels of young and aged rat brain using a simple yet relatively robust vessel
painting technique. We found global reduction in vascular parameters and significant
decline in the number of branches from the main middle cerebral artery indicative of
decreased cerebral blood flow to the aged brain consistent with previously published
reports. Given the importance of vascular structure in ischemic stroke, the compromise
in surface cortical vessel is suggested to contribute to worse functional outcomes
following cerebral ischemia observed in aged animals. This study sheds light on
understanding the biology of vascular aging and highlights the importance of using ageappropriate animals while studying specific diseases of aging. The selection of more
appropriate models will likely increase the success rate of stroke intervention research
that aims to translate preclinical findings.

FUTURE DIRECTIONS
Some unanswered questions in the field are 1) why these changes occur in the
aged brain and what propels them? 2) why are there region-specific microvascular loss
and what are the regional cues that could help predict heterogeneous vessel loss across
brain regions? 3) what are the cellular and molecular mechanisms underlying the biology
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of vascular aging? 4) how are the components of the neurovascular unit (NVU) altered
due to aging?
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A

B

Figure 3.1: Cerebral vasculature of rat brain visualized by vessel painting.
Representative images of cerebral vascular architecture showing dorsal, ventral, left and
right side view of A) Young and B) Aged rat brain. (n=6-7 animals/group)
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B

Figure 3.2: Surface Cortical Analysis of Total Brain. A) Basic morphometric and
spatial parameters- total area, vessel area, vessel density, number of junctions, junction
density, number of endpoints, total vessel length, average vessel length and lacunarity
calculated for surface cortical vessel of aged and young brain in the axial plane. B)
Representative skeleton image of young and aged brain after processing using the
AngioTool. (n=6-7 animals/group). Data reported as mean ± S.D.
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B

Figure 3.3: Surface Cortical Analysis of Middle Cerebral Artery (MCA). A) Basic
morphometric and spatial parameters- total area, vessel area, vessel density, number of
junctions, junction density, number of endpoints, total vessel length, average vessel
length and lacunarity calculated for right and left MCA of aged and young animals. B)
Representative skeleton image of young and aged brain after processing using the
AngioTool. (n=6-7 animals/group). Data reported as mean ± S.D.
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B

Figure 3.4: Vessel Diameter and Branch Order Analysis. A) Histogram of vessel
diameter in aged and young brains B) Histogram of branch order information of aged and
young MCA. (n=6-7 animals/group).
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CHAPTER FOUR

Characterization of age-related changes on leukocyte
populations following acute systemic inflammation in
Sprague Dawley rats
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ABSTRACT
As we age our immune system gradually degrades in function leading to
immunosenescence, which is associated with increased incidence and severity of several
chronic diseases, including cardiovascular, neurodegenerative diseases, cancer &
diabetes. Given the clinical implications of age-related changes in the immune system, a
critical gap in knowledge exists regarding how age changes immune response when
stimulated. Previous studies have identified many hallmark signs of immune aging.
However, what remains unknown are how aging changes the composition and
quantitative response of leukocytes in response to injury/disease. In the present study,
we investigated the impact age has on changes in major leukocyte populations in the
blood and spleen of young (3-4 months old) and aged (18-20 months old) female
Sprague-Dawley rats. We employed a robust flow-cytometric protocol to characterize
leukocyte populations in rats after subjecting them to lipopolysaccharide (LPS) challenge.
Rats were exposed to 0.9% saline or LPS (1 mg/mL) for 3 or 24 h after which, blood and
spleen were collected and analyzed. Results demonstrated an overall decline in leukocyte
numbers and increased numbers of B cells and natural killer (NK) cells in aged animals
as compared to young animals. Interestingly, while neutrophils saw modest increases in
expression in young LPS-treated rats at 24 h, a multi-fold increase in neutrophil counts
were measured in aged LPS-treated rats at 24 h. This study affirms that age provokes
several changes in the systemic immune response that can have dramatic effects on
response to injury/disease and underscores the importance of using age-appropriate
animals when exploring injury/disease.
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INTRODUCTION
A prominent feature of biological aging in mammals is a gradual but progressive
deterioration of cellular function over time that occurs across multiple organ systems
(Pawelec, 2018). This process, known as cellular senescence, is an influencing factor in
many age-related pathologies (Pawelec, 2018). Aging is a primary risk factor for several
chronic diseases, including cancers, cardiovascular disease, diabetes, stroke, and
neurodegenerative disorders (Niccoli and Partridge, 2012b; Haynes, 2020). Yet, when
researching the pathophysiology and treatment effectiveness in these diseases,
consideration of processes underlying normal aging are often ignored. This failure to
account for age-related changes, often referred to as aging hallmarks, may be an
underlying factor in the failure of so many treatments, especially in the neurological area,
to translate from promising preclinical studies into clinical practice (Kirkland, 2016).
Therefore, studies should evaluate age as a variable when studying animal models of
specific diseases (Jackson et al., 2017).
The relationship between biological aging and cellular senescence is complex as
the interaction between these two processes can, at times, be difficult to differentiate
(Fülöp et al., 2016; Pawelec, 2018). For example, as an individual ages, time-dependent
hallmark signs of aging, such as telomere erosion, metabolic slowing and increased
genomic instability begin to emerge as driving forces in perpetuating cellular senescence,
which, in turn, contributes to the development of other aging hallmarks, such as low-grade
inflammation, stem cell exhaustion, mitochondrial dysfunction and altered intercellular
communication (Fülöp et al., 2016; Pawelec, 2018). The interplay between different aging
hallmarks creates a vicious cycle resulting in aberrant responsiveness of cells to external
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stimuli and ultimately tissue dysregulation (Fülöp et al., 2016; Pawelec, 2018). A prime
example of this can be seen in the relationship between low-grade inflammation, often
referred to as inflamm-aging, and immunosenescence leading to progressive
deterioration in the ability to respond to infection in the older population (Fülöp et al.,
2016; Pawelec, 2018; Bischof et al., 2019). This age associated chronic systemic
inflammation not only increases mortality but also contributes to the development of
several neurological injuries and neurodegenerative diseases in the elderly (Ritzel et al.,
2018; Bischof et al., 2019; Barbé-Tuana et al., 2020; Chee and Solito, 2021; Finger et al.,
2021; Sykes et al., 2021).
For the past two decades, our lab has studied the effects of age on ischemic stroke
severity and recovery. Results of our studies, using comparative indicators of ischemic
stroke injury (infarct volume, brain swelling, functional recovery, mortality), definitively
show that aged rodents have worsened outcomes after ischemic brain injury than their
younger counterparts (Rosen et al., 2005; Lucke-Wold et al., 2012). In addition, several
studies have demonstrated how the age-related changes alter peripheral immune response
after stroke and hence influence stroke risk and outcome (Shaafi et al., 2014; Kim et al., 2018;
Ritzel et al., 2018; Aref et al., 2020; Sykes et al., 2021).
The objective of this study was to determine the effect(s) of aging on the acute
systemic immune response following lipopolysaccharide (LPS) challenge. We
hypothesized that immunosenescence in aged rats would lead to greater difficulty in
mounting an effective acute response following LPS administration. To assess response,
we stimulated an immune challenge by administering a single dose of LPS (1 mg/kg; i.p.)
in female Sprague-Dawley rats (2-3 and 18-20 months). Using flow cytometry and ELISA,
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we measured changes in leukocyte populations in blood and spleen & inflammatory
cytokine expression in plasma at 3 and 24 h following LPS administration.

MATERIALS & METHODS
Animals. Studies using rats were approved by the West Virginia University (WVU)
Animal Care and Use Committee and abided by ARRIVE guidelines. Forty-two female
Sprague-Dawley (SD) rats were used in this study (20 young; 22 aged). Aged female SD
rats (20-22 months) were acquired from our aging colony (Hilltop Laboratories; Scottdale,
PA) and young female SD rats (3-4 months) were purchased from Hilltop Laboratories.
Upon arrival, rats were housed in the WVU animal facility with food and water supplied
ad libitum.

Experimental design. Upon arrival, rats were randomly assigned to one of four treatment
groups within age category: Group 1- administered 0.9% sterile saline intraperitoneally
(i.p.) with tissue collection at 3 h after injection; Group 2- administered 0.9% sterile saline
(i.p.) with tissue collection at 24 h after injection; Group 3- administered
lipopolysaccharide (LPS; 1 mg/kg; i.p.; Sigma Chemicals; St. Louis, MO) with tissue
collection at 3 h after injection; Group 4- administered LPS (1 mg/kg; i.p.) with tissue
collection at 24 h after injection. Saline and LPS were filtered through a 22 mm syringe
filter before use. At specified time point, rats were anesthetized with 4% isoflurane
(Patterson) and blood collected (~5 ml) in citrated tubes from the left ventricle. After blood
draw, rats were cardiac perfused with ice-cold 0.9% saline for 10 min, at which time the
spleen was excised and weighed.
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Tissue processing. After collection, 2 ml of citrated blood was separated for flow
cytometry and the remaining blood centrifuged at 1500 x g for 10 min at 4C. Plasma was
collected and frozen at -20C until assayed. Leukocytes from the blood were isolated
using Lympholyte cell separation media for mammals (Cedarlane) according to
manufacturer’s instructions. Spleen was cut into small cubes, homogenized using a
dounce homogenizer, and centrifuged at 1300g for 10 mins. Cells were strained using a
40μM nylon mesh into a 50 ml conical tube. Red blood cells were lysed using 1x RBC
Lysis Buffer (Multi-species) from eBioscience™. Cell pellets were resuspended, and
Trypan blue dye was used to quantify the live cells using an automated cell counter
(Countess from Invitrogen) (as shown in Figure 4.1).

Flow cytometry. Cell lysates from blood and spleen were assessed using a 9-color
staining panel (Barnett-Vanes et al., 2016) with antibodies as detailed in Table 4.1. First,
5 x 105 cells were washed and stained with Live/Dead dye (eBioscience™; 1:1000) in 1X
phosphate buffered saline (PBS; pH=7.4). Next, cells were blocked with anti-CD32 to
mitigate Fc-mediated non-specific binding for 30min at 4C. Cells were then incubated in
antibody cocktail in 1X PBS containing 1% bovine serum albumin and 0.1% sodium azide
for 1h at 4C. At end of incubation, cells were washed and fixed in 0.4% paraformaldehyde.
Flow cytometric normalization was performed using fluorescent compensation beads
(AccuCount Blank Particles, Spherotech) and cells were analyzed on a multicolor flow
cytometer (LSRFortessa™, Becton-Dickinson). The fluorescence minus one principle
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was used to account for background antibody fluorescence in our positive and negative
gating of cell populations.

Multiplex Cytokine ELISA. Circulating cytokines (interleukin (IL)-1 beta (1b), IL-4, IL-5,
IL-6, IL-10, IL-13, interferon-gamma (IFN-ɣ), keratinocyte chemoattractant/growth
regulated oncogene (KC/GRO) & tumor necrosis factor alpha (TNF-α) were measured in
plasma samples collected at termination according to manufacturer’s instructions (Proinflammatory Panel 2 V-Plex kit (K15059D-1); MSD; Rockville, MD). Cytokine assays
were read using a MESO QuickPlex SQ 120 and data were analyzed using the MSD
Discovery Workbench software version 4.0. Lower limits of detection for cytokines
(pg/mL) were IL-4 (0.16), IL-5 (6.89), IL-6 (7.18), IL-10 (6.18), IL-13 (0.45), TNF-α (1.04),
IFN-ɣ (1.48). Due to several samples in the LPS-treated groups reaching upper limits of
detection for IL-6 & KC/GRO, these samples were repeated using a 1:10 dilution.

Statistical analysis. For leukocytes, raw counts were normalized using compensation
beads (10,000 counts for blood; 7,500 counts for spleen) and expressed as mean  SD.
For comparative evaluation of T lymphocytes, a percent of total cell-type population was
calculated by taking a ratio of CD4+, CD8+, CD4-/CD8- & CD4+/CD8+ counts to
compensated total T lymphocytes. For cytokine levels in plasma using multi-plex ELISA,
cytokine concentration in experimental groups was normalized to cytokine concentration
in plasma of naïve young and aged rats & expressed as mean  SD. Since variance in all
treatment groups were normally distributed, a three-way analysis of variance (ANOVA)
was used to determine statistical significance on main effects of treatment, time point &
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age followed by Tukey’s HSD post-hoc analysis to identify inter-group differences. Using
an a priori power analysis to calculate sample sizes, an n of 5 rats per treatment group
was deemed sufficient to calculate statistical significance with a P<0.05. All statistical
analyses were performed using Graph Pad Prism software.

RESULTS
LPS sickness behavior and mortality. Regardless of age, rats exposed to LPS (1
mg/kg; i.p.) exhibited signs of sickness behavior, including anhedonia, irritability and
lethargy that continued out to 24 h. At 24 h, other signs of sickness behavior were
observed, including loss of appetite, piloerection, and increased aggression. No young
rats experienced mortality during the 24 h of LPS exposure; however, aged rats
experienced 2 deaths out of the 12 aged rats exposed to LPS used in the study. Both rats
were in the LPS 24 h group. This 29% mortality rate in the LPS 24 h group was
significantly higher than observed in the aged PBS 24 h group and the combined 17%
mortality rate in the aged LPS group (3 & 24 h) was significantly higher than shown in the
young LPS group.

Gating strategy and characterization of leukocyte profiles using FACS. To obtain a
population of live single leukocytes (Figure 4.2), we employed a gating strategy in blood
and spleen that removed debris & not “live” cells (live/dead dye), gated to singlets using
FSC-H & FSC-W parameters to filter out doublets & clumps of cells and finally gated for
CD45+ (pan-leukocyte) cells, resulting in a population of live, single leukocytes for
sequential separation. T lymphocytes were gated as CD3+, natural killer (NK) cells were
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gated as CD161+, B cells as CD45R+; neutrophils as CD43+ and higher granularity and
finally monocytes as differential expression of CD43 (CD43Hi and CD43Lo).

Age-related changes in spleen and body weight. Next, we wanted to investigate the
age-related changes in body & spleen weights and splenocyte count after LPS challenge
in rats (as shown in Table 4.2). We observed increase in spleen weight upon LPS
administration irrespective of the age. Spleen weight was increased in aged LPS 3h
compared to young LPS 3h group. We also noticed that the body weight increased upon
aging. We then normalized spleen weights to body weights and noticed that spleen/body
weight ratio was increased upon LPS treatment. Overall, there was a decrease in the
number of splenocytes due to aging. In addition, aged animals showed an increase in
spleen count upon LPS treatment at 3h. The number of splenocytes plummeted at 24h
post LPS treatment irrespective of age. Further, the number of splenocytes was
normalized to spleen weight and we noticed LPS induced decrease in the total spleen
count by spleen ratio in the young animals while an increase in the total spleen count by
spleen ratio in aged LPS 3h.

Quantification of leukocyte populations in blood. Using flow cytometry, we isolated &
quantified leukocyte populations from whole blood in young and aged female rats at 3
and 24 h after LPS challenge. Regardless of the age, LPS challenge significantly reduced
total leukocytes (p<0.01), T cells (p<0.0001 for young; p<0.05 for aged), B cells (p<0.05
for young; p<0.0001 for aged) in the blood at 3 and 24 h when compared to age-matched
PBS treated rats (as shown in Figure 4.3). As Figure 4.3A indicates there was no
difference in total white blood cell (CD45+) counts measured between PBS-treated rats
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at 3 and 24 h in young (p=0.9998) or aged (p=0.2361). Likewise, comparison of young
PBS-treated rats to aged PBS-treated rats showed no difference (p=0.9995) in circulating
total leukocytes. In aged rats, a significant (p=0.01) increase in total leukocytes was
observed at 24 h after LPS challenge in the aged rats when compared to 24 h in young
rats. Regardless of age, no difference (p>0.05) in total leukocytes was measured within
LPS-treated rats between the 3 and 24 h time points. As Figure 4.3B illustrates there was
a no difference (p>0.05) in circulating T lymphocytes (CD3+) between PBS-treated rats at
3 and 24 h in young or aged. Similarly, no difference (p>0.05) in T lymphocyte counts
were demonstrated between LPS-treated rats at 3 and 24 h after LPS challenge in young
or aged rats. A significant (p<0.05) age effect was shown in PBS-treated rats with a
marked reduction in circulating T lymphocytes observed in aged rats at 3 and 24 h when
compared to young rats. Conversely, Figure 4.3C indicates increased B lymphocytes in
aged PBS treated rats when compared to young PBS treated rats (p=0.0056). As Figure
4.3D shows NK cells were significantly increased (p<0.05) at 24h compared to 3h LPS
treatment in the aged animals. Additionally, there was a significant difference (p=0.0021
for PBS; p=0.0040 for LPS) in the main effect of age with aged rats having increased
circulating NK cells regardless of treatment (Figure 4.3D). A similar trend was observed
for monocytes which showed a significant increase (p<0.0001 for PBS; p=0.0078 for LPS)
in number due to aging, irrespective of the treatment (Figure 4.3F). In addition, Figure
4.3F shows that monocytes population was significantly decreased (p<0.01) at 3h
compared to 24h LPS treatment in the aged animals. It is also interesting to note that the
neutrophil count was significantly increased (p<0.0001) in aged LPS treated rats at 24 h
(Figure 4.3E).
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Quantification of leukocyte populations in spleen. The spleen leukocyte populations
were isolated & quantified in young and aged female rats at 3 and 24 h after LPS
challenge using flow cytometry. Overall, aged rats exhibited reduced leukocyte counts at
both 3 and 24 h in the spleen when compared to young rats irrespective of the treatment
(Figure 4.4). Aged animals showed a significant decrease in white blood cells (p<0.0001),
T lymphocytes (p<0.0001), B lymphocytes (p<0.0001), NK cells (p<0.05 for LPS and
PBS) and monocytes (p<0.0001 for PBS; p=0.013 for LPS) when compared to young
animals (Figures 4.4A, B, C, D & F). Additionally, monocyte population was significantly
decreased (p<0.001) at 24h compared to 3h LPS treatment in aged animals (Figure 4.4F).
Interestingly, neutrophil counts in the spleen were significantly increased (p<0.01) in
young LPS treated rats at 24 h while the numbers were significantly decreased
(p<0.0001) in aged LPS treated rats at 24 h (Figure 4.4E).

Measurement of inflammatory cytokines in plasma. Using MSD multiplex rat ELISA
kit, we measured pro-inflammatory cytokine expression in the plasma of aged and young
rats at 3 h and 24 h after LPS challenge, according to manufacturer’s instructions.
Regardless of age, LPS challenge significantly increased IL-4 levels (p<0.0001 in case of
young; p<0.01 in case of aged) in the plasma at 3 and 24 h compared to PBS treatment
(Figure 4.5A). In case of young animals, this effect was prominent at 24h (p<0.0001
versus 3h) upon LPS stimulation (Figure 4.5A). However, aged animals had significantly
reduced (p<0.0001) IL-4 expression than young animals at 24h after LPS administration
as seen in Figure 4.5A. Conversely, aged animals showed significant increase (p<0.05)
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in IL-5 expression at 24h post LPS stimulation compared to young rats (Figure 4.5B).
Additionally, this increase was significantly higher at 24h (p<0.01) compared to 3h post
LPS treatment in the aged animals. Regardless of age, IL-5 expression in plasma is
significantly increased (p<0.01 for young; p<0.0001 for aged) upon LPS challenge versus
PBS treatment at 24h (Figure 4.5B). Similarly, IL-10 & IL-1 expression was significantly
increased upon LPS stimulation irrespective of age at 3h and 24h (Figure 4.5C & F). This
increase was significantly higher (p<0.05) at 24h compared to 3h in LPS treated aged
animals in case of IL-10 expression as seen in Figure 4.5C. Figure 4.5 C & F shows no
age-related change in expression of IL-10 (p=0.8651) & IL-1 (p=0.3675) while Figure 4.5
D & E shows no significant changes (p>0.05) in the expression of IFN & IL-13 across the
groups. There was significant difference in the main effect of time point with increased
(P<0.0001) IL-6, CXCL-1 & TNF expression at 3h while decreased (p<0.0001)
expression at 24h upon LPS challenge irrespective of age (Figure 4.5G, H &I). However,
at 24h post LPS treatment IL-6 and CXCL-1 levels were significantly increased in aged
(p<0.05) compared to young animals (Figure 4.5 G & H). Apart from treatment & time
point related effect, TNF also showed age related effect with significantly decreased
(p<0.01) levels in aged LPS treated rats as opposed to young LPS treated rats at 3 h
(Figure 4.5 I).

DISCUSSION

The immune system is a dynamic network that is tightly regulated to ensure
effective protection against foreign antigens. With increasing age, it undergoes a
remodeling process characterized by a decline in immune cell function due to cell intrinsic
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and extrinsic factors (termed as immunosenescence) accompanied by chronic low-grade
inflammation (termed as inflamm-aging). This dysregulation of the immune system seen
in elderly increases their susceptibility of developing chronic, infectious diseases and
decreases the effectiveness of vaccines (Ciabattini et al., 2018). With rising life
expectancy of the global population, understanding the impact of age on our immune
system is utmost priority to improve the quality of life and decrease the burden on the
healthcare. While it has been established that the aging process undergoes several
changes and thus does not produce adequate response against infection, data regarding
the cellular analysis in response to acute systemic inflammation is limited. Peripheral
blood leukocyte count is routinely examined to detect systemic infection and is useful for
determining the underlying pathological conditions (W Chen et al., 2021). In this study,
we investigated the age-related differences in leukocyte response following LPS induced
acute systemic inflammation in female Sprague Dawley rats. We administered the
endotoxin Lipopolysaccharide (LPS), an important component of Gram-negative
bacterium cytoderm (Ronco et al., 2014) to mimic systemic inflammation in humans. We
employed a robust 9-colour flow cytometric method (Barnett-Vanes et al., 2016) to
effectively characterize the major rat leukocyte population in the blood and spleen.
Herein, we report an age-related increase in NK cells, monocytes and neutrophils in the
circulation accompanied by a decline in major leukocyte population in the spleen. In
addition, we observed a shift in cytokine expression towards a pro-inflammatory
phenotype in the aged animals compared to young animals treated with LPS.

White blood cells of the immune system are derived from the progenitor or
precursor cells called the hematopoietic stem cells in the bone marrow. In the context of
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healthy aging, there is a shift towards myeloid cell populations relative to lymphoid cell
populations in circulation (Mogilenko et al., 2021). This gradual expansion of myeloid cell
populations is partly due to age-related thymic involution resulting in alteration of T-cell
composition and T-cell related immuno-incompetence (Gui et al., 2012). In addition, there
is skewing of the hematopoietic compartment towards myelopoiesis concomitant with the
loss of lymphoid-committed progenitors in the aging bone marrow thereby decreasing the
peripheral adaptive immune populations (Almanzar et al., 2020; Krishnarajah et al.,
2021). Accordingly, we noticed a decline in the overall number of lymphocytes (T cells +
B cells + NK cells) while the number of monocytes were increased in the circulation of
aged animals compared to young animals. Taking a closer look at the individual
lymphocytes, we found significant age-related increase in the population of NK cells in
circulation. NK cells are the primary population of innate lymphoid cells that protects
against viral infection. We distinguished rat NK cells based on CD 161 expression, which
marks innate proinflammatory cytokine-responsive subtype of NK cells (Kurioka et al.,
2018). Recent evidence showed that aged individuals had a diminished proportion of the
immature (CD56bright) NK population while increased population of mature (CD56dim),
late, low cytotoxic NK cells (Zheng et al., 2020). Thus, increased number of
proinflammatory NK cell subtype is required by the aged animals to induce cell
cytotoxicity. However, immunosenescence of NK cells due to aging causes the NK cells
to lose their capacity for antiviral activity thereby increasing the incidence of infections in
elderly (Zheng et al., 2020). With respect to adaptive immune system, we observed a
significant decrease in CD3+ T cells which may be due to shortening of telomere length
leading to delayed clearance of pathogens and prolonged duration of infection (Yu and
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Zheng, 2019). On the other hand, the circulatory B cells were significantly increased in
the aged rats when compared to young rats. It is known that aging promotes the
polarization of naive T cells and B cells to age-associated, exhausted and regulatory
phenotype (Frasca et al., 2011; Lin et al., 2016; Zheng et al., 2020). Additionally, aging
causes slow turnover and inability of new B cells to effectively replenish the peripheral
mature B cell populations (Johnson et al., 2002). This leads to rapid decline in humoral
response and correlate with poor response to vaccination in addition to shortening the
time interval between booster doses in the elderly (Ciabattini et al., 2018). Although the
number of circulating monocytes is increased with age, they are not capable of clearing
bacterial infection due to premature release from the bone marrow (Puchta et al., 2016).
We also observed significant increase in monocytes levels in circulation of aged animals
compared to young animals after LPS stimulation at 24h. In older subjects, monocytes
are increased upon chronic inflammatory conditions and produce increased
proinflammatory cytokines such as IL6, TNF, IL1β (Puchta et al., 2016) consistent with
our observation. Furthermore, aging alters the gene expression in monocytes leading to
increased risk of cardiovascular mortality, coronary artery plaque formation and
atherosclerosis (Choi et al., 2017; Saare et al., 2020). Such age-related physiological
changes in the immune system predisposes the elderly to infectious diseases (Esme et
al., 2019). A recent study showed a strong correlation between the ratios of circulating
myeloid cells and lymphocytes with blood coagulation parameters and disease severity
in case of COVID-19 (Ma et al., 2021), which predominantly affected individuals 65 years
and above (Yanez et al., 2020; Guerrero and Wallace, 2021). The authors found
increased neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR),
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and basophil-to-lymphocyte ratio (BLR) in critically ill/deceased patients (Ma et al., 2021).
Thus, careful attention should be paid to changes in WBC count in elderly subjects as
leukocyte count has a potential clinical implication in predicting mortality as well as longterm survival (Nilsson et al., 2014).

Neutrophils are the most abundant cellular component of the innate immune
system that provide protection against bacterial or fungal infection (Butcher et al., 2000).
They are primary cellular responders that are recruited at the site of injury/infection
through extravasation across the vascular barrier in response to specific chemotactic and
pro-inflammatory signals (Fine et al., 2020). Neutrophils levels are increased in response
to sterile and nonsterile inflammation. Nishio and colleagues reported increased numbers
of neutrophils required for wound repair in elderly subjects (Nishio et al., 2008). During
systemic inflammatory conditions such as sepsis, the mean volume of neutrophils was
increased and can be used a promising hematologic parameter for differentiating elderly
patients with and without sepsis (Lee and Kim, 2013). Overall, elevated neutrophil levels
negatively impact the health-related quality of life (Wouters et al., 2021). In the context of
healthy aging, neutrophil counts were found to be increased in circulation of aged subjects
irrespective of sex (Valiathan et al., 2016; Menees et al., 2021; Serre-Miranda et al.,
2022). This may be offset by decreased phagocytic ability leading to impairment in the
ability to clear pathogens and thus increased susceptibility to infection in the aged
population (Butcher et al., 2000). Additionally, hyper segmented, functionally
compromised neutrophil populations were accumulated in the splenic white pulp due to
decreased apoptosis with advancing age (Tomay et al., 2018). In accordance, although
not significant, we noticed an increasing trend for neutrophils in aged rats compared to
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young rats upon vehicle treatment suggesting a compensatory mechanism for the
reduced functionality of aged neutrophils. Furthermore, neutrophil diapedesis and
chemotaxis is impaired with aging (Brubaker et al., 2013; Uhl et al., 2016; Barkaway et
al., 2021). Studies have demonstrated that neutrophils exhibit reverse transendothelial
migration (rTEM) by traversing the endothelium in the reverse direction and thus reentering the circulation (Burn and Alvarez, 2017). While some studies showed rTEM of
neutrophils have anti-inflammatory effects and resolve chronic tissue inflammation others
demonstrated its role in disease progression (Burn and Alvarez, 2017). A recent report
from Barkaway et al., 2021 demonstrated increased levels of neutrophil reverse
transendothelial migration (rTEM) in aged mice due to dysregulated local inflammatory
milieu allowing pathogenic neutrophils to disseminate to distal organs and cause damage
(Barkaway et al., 2021).

The authors showed that rTEM is propelled by increased

expression of CXCL-1 produced by mast cells located at the endothelial cell junction
(Barkaway et al., 2021). Consistent with this report, we saw elevated expression of CXCL1, a major chemokine for neutrophil attraction, in the plasma at 24h post stimulation with
LPS. In the present study, we showed age-related significant increase in neutrophil
counts in peripheral blood at 24h after LPS induced systemic inflammation, which is the
major finding of the paper. This age-related neutrophilia observed in circulation is merely
not a response to systemic inflammation but also due to release of immature neutrophils
from marginated pools such as spleen demonstrated by decreased splenic neutrophils at
24h after LPS induced acute systemic infection. Recent reports showed that neutrophils
are heterogeneous, with specific neutrophil sub-populations in the marginated pools
(lungs, liver and spleen, in addition to bone marrow) and executing distinct functions
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(Christoffersson and Phillipson, 2018; Herrero-Cervera et al., 2022). For example,
recently Deniset and colleagues identified a novel neutrophil subsets Ly6G hi and
Ly6Gintermediate residing in the murine splenic red pulp region and demonstrated their role
in the clearance of systemic S. pneumoniae by eliciting rapid innate immune response in
vivo (Deniset et al., 2017). Taken together, it will be interesting to know if a specific
population of neutrophil is associated with rTEM and thus help identify novel therapeutic
targets aimed at preventing distant organ damage especially in the older adults.

The spleen is the second largest lymphoid organ and plays an important role in the
maintaining the homeostasis by acting as a blood filter (Lewis et al., 2019). The spleen is
considered the storage unit primary for T cells, B cells, NK cells, macrophages, and DCs
whose function is to eliminate encapsulated bacteria as well as elicit central and
peripheral immune tolerance (Aw et al., 2016; Turner and Mabbott, 2017). More recently,
the existence of monocytes and neutrophils reserves in the spleen were discovered
(Swirski et al., 2009; Puga et al., 2011). Aging causes splenic structural modifications
noticeably in the marginal zone and white pulp region (Turner and Mabbott, 2017). This
is indicative of changes in the number and distribution of immune cell population housed
within the microarchitecture of the spleen thereby affecting its function (Turner and
Mabbott, 2017). Accordingly, we showed overall immunosuppression in the total number
of leukocytes, T cells, B cells, monocytes, and NK cells in the spleen of aged animals
compared to young animals leading to deterioration of cellular and humoral immune
system with age. This is accompanied by significant increase in B cells, monocytes, and
NK cells in the circulation. We also observed decreased spleen to body weight ratio along
with reduced number of splenocytes per gram of spleen due to aging consistent with
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previous findings (El-naseery et al., 2020; Menees et al., 2021). Taken together, our data
suggests age-related impairment in the ability to retain immune cell reservoirs in the
spleen. Several studies have investigated the role of spleen in initiating peripheral
immune response to brain injury such as ischemic stroke (Liu et al., 2015; Pennypacker
and Offner, 2015). In vivo studies showed that splenectomy prior to cerebral ischemia
significantly decreased neurodegeneration by blunting systemic inflammation in young
and aged animals (Ajmo et al., 2008; Chauhan et al., 2018; Seifert and Offner, 2018).
Additionally, splenectomy reduced peripheral inflammatory cytokine levels as well as
decreased macrophages, neutrophils, B cells, and T cells infiltration into the brain at the
site of injury thereby attenuating ischemic brain damage (Ajmo et al., 2008; Chauhan et
al., 2018; Seifert and Offner, 2018). Given the fact that the incidence and mortality rate of
stroke is higher in the aged population (Avan et al., 2019; Yousufuddin and Young, 2019),
the effect of age on splenic response following splenectomy in contributing cerebral
ischemia induced brain damage is warranted.

Aging is characterized by disruption of the cytokine homeostasis and skewing
towards a proinflammatory state termed as inflamm-aging (Rea et al., 2018). Overall, we
saw increase in cytokine levels upon LPS stimulation irrespective of age and time
(Seemann et al., 2017). Our data showed elevated levels of pro inflammatory cytokines
(TNF-α, IL-1β, IL-6, CXCL-1) in the plasma upon LPS challenge at 3h and the values
seemed to return to baseline at 24h after LPS treatment. On the other hand, we noticed
significant changes in anti-inflammatory cytokines with increased IL-10 and IL-5
expression and concomitant decrease in IL-4 levels upon LPS stimulation at 24h in the
aged rats. IL-6, TNF-α and IL-1β are key pro-inflammatory cytokines that have been
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implicated in autoimmune diseases, bacterial infections, cardiovascular disease, (Kany
et al., 2019) and more recently COVID-19 (Ragab et al., 2020). Understanding the
cytokine profiles of aged individual is particularly important in diseases like COVID-19,
that predominantly affects the older populations resulting in increased hospitalization and
mortality, to help clinicians classify patients based on the severity of infections (Angioni
et al., 2020). Elevated levels of pro-inflammatory cytokines are known to increase the risk
of cardiovascular diseases, frailty, as well as cognitive impairment (Ferrucci and Fabbri,
2018). Our data showed elevated levels of IL-6 and CXCL-1 at 24h after LPS treatment
in the aged group compared to the young LPS 24h group indicating prolonged systemic
inflammation after LPS stimulation upon aging. Increased expression of plasma/serum
IL-6 levels positively correlated with poor stroke outcomes and may serve as a prognostic
marker (Shaafi et al., 2014; Aref et al., 2020; Mosarrezaii et al., 2020). Additionally,
prolonged LPS induced systemic inflammation is dangerous as it results in disruption of
the blood brain barrier thereby allowing infiltration of inflammatory immune cells (Fu et
al., 2014). This in turn can drive neuroinflammation leading to secondary
neurodegeneration following stroke (Stuckey et al., 2021). Accumulating evidence has
shown that chronic inflammation is associated with age-related memory and cognitive
decline (Sartori et al., 2012; Fielder et al., 2020). All these events negatively impact the
CNS and contribute to disease pathologies such as Alzheimer disease, Parkinson
disease, and other neurodegenerative diseases which predominantly affect the elderly
(Hou et al., 2019). Given the importance of chronic inflammation in driving multiple CNS
pathologies, anti-inflammatory and immunomodulating agents appear to be attractive
treatment options in providing neuroprotection.
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One particular caveat is that this study was conducted in female rats. Growing
body of literature demonstrated that immune cell profile and responses to both self and
foreign antigens is altered based on sex differences (Gubbels Bupp, 2015; Klein and
Flanagan, 2016; Díaz et al., 2020; Márquez et al., 2020; Breznik et al., 2021; SerreMiranda et al., 2022). Future study will focus on investigating the cellular composition and
the cytokines levels following infection using male animals. In vivo endotoxemia model
using LPS, an important component of Gram-negative bacterium cytoderm (Ronco et al.,
2014), was employed to mimic acute systemic inflammatory response. However, varying
dosages of LPS differentially regulated cytokine expression indicating a dose-dependent
accumulation of leukocytes in vivo (Larsson et al., 2000; Morris et al., 2014). Along those
lines, a recent study conducted in SD rats tested three different concentrations of LPS
and found 10mg/kg to be effective in inducing sepsis as evidenced by significant
modulation of blood, biochemical and molecular markers (Bhardwaj et al., 2020).
Additionally, the study confirmed that male rats are more susceptible to infections than
female rats (Bhardwaj et al., 2020) indicating the need for increased dose of LPS to elicit
the same response in females. In the present study we used a single dose of 1mg/kg
LPS, which probably was not significant to induce a robust immune response in the
female SD rats. A more extensive evaluation of peripheral immune system components
following chronic LPS exposure is warranted. Studies showed that aged animals showed
phenotypic changes in both lymphoid and myeloid lineages in a diverse range of tissue
and organs (Almanzar et al., 2020; Krishnarajah et al., 2021), and thus leading to potential
differences in cell cytotoxicity in response to injury/disease. For example, dentate gyrus
resident NK cells are increased in the brains of healthy aged adults and result in NK
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dependent depletion of neuroblasts leading to cognitive decline and reduced
neurogenesis (Jin et al., 2020). However, in the current study we focused on changes in
major leukocyte population specifically in the blood and spleen in the presence and
absence of LPS induced systemic infection. It would be interesting to understand age
related alteration in other tissues following LPS challenge as well. Future studies should
focus on delineating the mechanism of immunosenescence in each tissue following acute
infection with advancing age.

CONCLUSION
In summary, our study provides a reference data set for major leukocyte
populations and pro- and anti-inflammatory cytokines in blood and spleen of young and
aged rats with and without LPS treatment. The response to brain injury following
neurological disorders such as stroke is greatly determined by peripheral immune system.
Age-associated changes in the systemic immune response can alter brain vasculature
and drive chronic neuroinflammation which worsens stroke outcome in the elderly. This
study highlights the importance of age-related changes on systemic immune response
and underscore the importance of choosing the correct age based on development or
cellular aging of the system being studied. Future studies should focus on development
of novel therapies to target the peripheral immune system such as bone marrow
rejuvenation, which holds great promise for the treatment of neurological diseases.
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Figure 4.1: Schematic showing the processes involved in sample processing and
analysis. Major leukocyte population in the blood and the spleen were analyzed by flow
cytometry and the cytokines/chemokines in the plasma were analyzed by ELISA (Created
in BioRender.com).
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Figure 4.2: Gating strategy to identify major leukocyte populations in aged and
young rats. Blood (not shown) and spleen were processed, analyzed and the relative
proportion of each leukocyte population presented was presented. (n=5 animals/group).
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Figure 4.3: Changes in circulating leukocytes after LPS challenge. Rats were
administered LPS or saline, followed by which blood was collected either 3h or 24h,
processed and analyzed. (⁎ denotes difference compared to young PBS 3h, # denotes
difference compared to young PBS 24h, $ denotes difference compared to aged PBS 3h,
% denotes difference compared to aged PBS 24h, & denotes difference compared to aged
PBS 24h, / denotes difference compared to young LPS 24, + denotes difference compared
to aged LPS 3h, @,! denotes difference compared to aged PBS 24h; %,*, #, $, + p < 0.05, ##,$$,
&&p < 0.01, ⁎⁎⁎, &&&, ###p < 0.001, ⁎⁎⁎⁎, $$$$, %%%%, ////, !!!!, ++++, ####p < 0.0001). Data are
presented as mean ± SD; n=5 animals/ group.
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Figure 4.4: Changes in splenic leukocytes after LPS challenge. Rats were
administered LPS or saline, followed by which spleen was collected either 3h or 24h,
processed and analyzed. Data are presented as mean ± SD; n=5 animals/ group.
(⁎ denotes difference compared to young PBS 3h, # denotes difference compared to
young PBS 24h, $ denotes difference compared to aged PBS 3h, % denotes difference
compared to aged PBS 24h, & denotes difference compared to aged PBS 24h, / denotes
difference compared to young LPS 24, + denotes difference compared to aged LPS 3h,
@,! denotes difference compared to aged PBS 24h; %,*, #, $, + p < 0.05, ##,$$, &&p < 0.01, ⁎⁎⁎,
&&&, ###p < 0.001, ⁎⁎⁎⁎, $$$$, %%%%, ////, !!!!, ++++, ####p < 0.0001). Data are presented as mean ±
SD; n=5 animals/ group.
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Figure 4.5: Plasma cytokine expression after LPS stimulation. Rats were
administered LPS or saline, followed by which changes in plasma pro-and antiinflammatory cytokine levels were measured at 3 h and 24 h. Data are presented as mean
± SD; n=5 animals/ group. (⁎ denotes difference compared to young PBS 3h, # denotes
difference compared to young PBS 24h, $ denotes difference compared to aged PBS 3h,
% denotes difference compared to aged PBS 24h, & denotes difference compared to aged
PBS 24h, / denotes difference compared to young LPS 24, + denotes difference compared
to aged LPS 3h, @,! denotes difference compared to aged PBS 24h; %,*, #, $, + p < 0.05, ##,$$,
&&p < 0.01, ⁎⁎⁎, &&&, ###p < 0.001, ⁎⁎⁎⁎, $$$$, %%%%, ////, !!!!, ++++, ####p < 0.0001). Data are
presented as mean ± SD; n=5 animals/ group.
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Table 4.1: Monoclonal antibodies for leukocyte characterization
Antibody

Flurochrome

Dilution

Supplier

Live-Dead

eFluor 780

1:1000

eBioscience

CD 32

N/A

1:200

BDPharmingen

CD 45

Alexa-Fluor700

1:100

Biolegend

CD 3

BV 421

1:100

BDBioscience

CD 43

PE

1:200

Biolegend

His 48

FITC

1:200

eBioscience

CD 161

APC

1:200

Biolegend

CD 45R (B220)

PE-Cy7

1:200

eBioscience

Table 4.2: LPS induced changes in body and spleen weight in the context of aging
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CHAPTER FIVE
Novel mitoNEET ligand NL-1 improves therapeutic outcomes
in an aged rat model of cerebral ischemia/reperfusion injury

This work is published in Exp Neurol. 2022 Sep;355:114128.
doi: 10.1016/j.expneurol.2022.114128. Epub 2022 Jun 2. PMID: 35662609.
Vijikumar A, Saralkar P, Saylor SD, Sullivan PG, Huber JD, Geldenhuys WJ.
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ABSTRACT
Cerebral ischemic stroke is a leading cause of mortality and disability worldwide.
Currently, there are a lack of drugs capable of reducing neuronal cell loss after
ischemia/reperfusion-injury after stroke. Previously, we identified mitoNEET, a [2Fe-2S]
redox mitochondrial protein, as a putative drug target for stroke. In this study, we tested
the novel mitoNEET ligand, NL-1, in a preclinical model of ischemic stroke with
reperfusion using aged female rats. Using a transient middle cerebral artery occlusion
(tMCAO), we induced a 2 h ischemic injury and then evaluated the effects of NL-1
treatment on ischemic/reperfusion brain injury at 24 and 72 h. Test drugs were
administered at time of reperfusion via IV dosing. Results demonstrated that NL-1 (10
mg/kg) treatment markedly reduced infarct volume and hemispheric swelling in the brain
as compared rats treated with vehicle or a lower concentration of NL-1 (0.25 mg/kg).
Surprisingly, the protective effect of NL-1 was significantly improved when encapsulated
in PLGA nanoparticles, where a 40-fold lesser dose (0.25 mg/kg) of NL-1 produced an
equivalent effect as the 10 mg/kg dose. Evaluation of changes in blood-brain barrier
(BBB)

permeability

and

oxidative

stress

using

immunohistochemical

staining

corroborated the protective actions of NL-1, showing reduced extravasation of IgG and
decreased levels of 4-hydroxynonenal (4-HNE) in the brains of aged female rats at 72 h
after tMCAO with reperfusion. Our studies indicate that targeting mitoNEET following
ischemia/reperfusion-injury is a novel drug target pathway that warrants further
investigation.
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INTRODUCTION
Ischemic stroke is a leading cause of death and disability in the United States; yet,
with the exception of reperfusion of infarcted tissue by thrombectomy, no other options
are approved for stroke treatment. Early reperfusion of infarcted tissue using tissue
plasminogen activator or endovascular mechanical devices is associated with lower rates
of death and improved health outcomes compared to stroke patients not receiving
treatment (Yang et al., 2021). However, reperfusion is not without risks and can result in
reperfusion injury, which is characterized by increases of reactive oxygen species (ROS)
formation, oxidative stress, blood-brain barrier (BBB) disruption & neuroinflammation
which leads to greater loss of vulnerable neurons adjacent to the infarct core (Jurcau and
Ardelean, 2021; Yang et al., 2021). Reperfusion injury following ischemia is clinically
noted by hemorrhagic transformation, increased vasogenic edema, infarct expansion and
neurologic worsening (Mandalaneni et al., 2020; Imran et al., 2021; Jurcau and Ardelean,
2021).
Recent studies demonstrate that cerebral ischemia and post-ischemic reperfusion
causes a wide array of mitochondrial dysfunction resulting in a sequelae-of-events
leading to ATP depletion, increased oxidative stress, changes in mitochondrial dynamics
and ultimately neurodegeneration (Mandalaneni et al., 2020). Conceptual views of
mitochondrial function have changed due to advances in our understanding of how
mitochondria work together within an integrated network to dynamically remodel and
reorganize to meet energetic demands of the cell. When these changes cannot be
accomplished, mitochondrial dysfunction results in a diminished ability of cells to meet
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energetic demand (Wu et al., 2021). Within the past decade, ischemic stroke has gained
greater attention for effects of mitochondrial dysfunction on neuronal death following
ischemic/reperfusion insult. Targeting mitochondria for treatment of post-stroke brain
injury has mainly focused on reducing neuron destruction by attenuating ROS formation
(Galkin, 2019).
MitoNEET is an iron‑sulfur [2Fe-2S] cluster protein embedded in the outer
mitochondrial membrane that functions to regulate oxidative capacity within mitochondria
by acting as a pH and redox sensor (Tamir et al., 2015). Prior studies indicate that
mitoNEET plays a protective role in the brain following neurological injury and disease
and demonstrate that targeting mitoNEET may be a valuable therapeutic approach to
mitigate the severity of reperfusion injury following ischemic stroke (Geldenhuys et al.,
2014; Tamir et al., 2015).
NL-1 (Figure 5.1) is a first-in-class compound designed based off of the
thiazolidinedione structure of pioglitazone, a drug marketed for its function as a nuclear
peroxisome proliferator-activated receptor gamma (PPARγ) agonist (Geldenhuys et al.,
2010). Pioglitazone, an anti-diabetic drug, has demonstrated neuroprotective activity in
several neurological disorders, including Parkinson's disease, Alzheimer's disease and
ischemic stroke (Yonutas and Sullivan, 2013). In preclinical neurodegenerative models,
pioglitazone administration reduced oxidative stress, decreased ROS formation and
diminished neuroinflammation. Following ischemic stroke, pioglitazone and rosiglitazone
protected neurons in the brain from mitochondrial dysfunction and pioglitazone prevented
mitochondrial-associated apoptosis (Culman et al., 2012; J Chen et al., 2021). These
promising findings were found to be an off-target effect of thiazolidinedione compounds
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at mitoNEET; however, due to unfavorable side effects (edema formation, bone loss and
heart failure) of the glitazones, it has necessitated the development of lead compounds,
such as NL-1, that selectively target mitoNEET without PPARγ activity (Saralkar et al.,
2020, 2021).
In the current study, we evaluated the efficacy of NL-1 treatment on
ischemia/reperfusion injury in aged female rats following a transient middle cerebral
artery occlusion (tMCAO). Using a 2 h ischemia followed by reperfusion, we assessed
neurologic outcome, infarct volume and hemispheric swelling at 24 h and indices of BBB
disruption, oxidative stress and apoptosis at 72 h after tMCAO. Results of this study
validated that NL-1 has a dose-dependent therapeutic potential to improve tissue sparing
following ischemia/reperfusion injury in the brain by decreasing vasogenic edema,
reducing BBB disruption and attenuating neuroinflammation and provides compelling
supportive evidence that mitoNEET functions as a therapeutic target for treatment of
ischemic stroke.

MATERIALS & METHODS
Drugs and chemicals. All chemicals were obtained from commercial sources. The
mitoNEET agonist, NL-1, was synthesized using Knoevangel condensation as previously
described (Geldenhuys et al., 2010). Prior to administration, NL-1 was freshly prepared
by dissolving a known amount of NL-1 in 100% methanol then evaporating the solvent.
Dried NL-1 was then reconstituted in ethanol (2% v/v) in phosphate buffered saline (PBS;
pH 7.4) with Tween-80 (2% w/v) to final doses of 0.25 and 10 mg/kg. PBS with 2% ethanol
and 2% Tween-80 served as vehicle (negative control). NL-1 (0.25 mg/kg) loaded poly

95

D,L-lactic-co-glycolic acid (PLGA) nanoparticles (NL-1 NP) were prepared using
emulsification and solvent evaporation as previously described (Geldenhuys et al., 2011).
Unentrapped (free) NL-1 was separated from NL-1 loaded nanoparticles by gel filtration.
The dose of NL-1 NP was restricted to 0.25 mg/kg due to physical limitations of the
encapsulation process used and to ensure volume of drug administered i.v. through the
tail vein did not exceed 0.5 ml. Based on these constraints, we tested free NL-1 at 0.25
mg/kg and 10 mg/kg. Experimental compounds and vehicle were filtered through a 0.22
μm syringe filter prior to administration.

Animals and experimental design. All animal procedures were approved by the West
Virginia University Animal Care and Use Committee prior to experimentation and abided
by ARRIVE 2.0 guidelines (Percie du Sert et al., 2020). Female Sprague-Dawley rats (22–
24 months) were acquired from our aging colony located at Hilltop Laboratories
(Scottdale, PA) and housed in the West Virginia University animal facility under 12 h lightdark conditions with food and water available ad libitum. Upon arrival, rats were randomly
assigned to one of four treatment groups (vehicle, NL-1 (0.25 mg/kg; i.v.), NL-1 (10 mg/kg;
i.v.) or NL-1 NP (0.25 mg/kg; i.v.) at one of two time points (24 h (n = 5 rats/group) or 72
h (n = 3–4 rats/group)). A sham group was included for 4-HNE studies (n = 3) and a naïve
group was included for the iron accumulation study (n = 3). Rats at 24 h after tMCAO
were assessed for changes in neurological function, infarct volume and hemispheric
swelling, while rats at 72 h after tMCAO were qualitatively assessed for changes in IgG
extravasation (a marker of BBB disruption), 4-HNE, a marker of lipid peroxidation or
TUNEL positive cells, a marker of cell death. To reduce bias and improve scientific rigor,
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dose administered was randomly assigned, surgeon was blinded to treatment groups,
immunohistochemistry was visualized and assessed separately by 2 investigators blinded
to treatment groups and data analysis was performed by investigator blinded to treatment
groups.

MCAO procedure. Using aged (22–24 months) female Sprague-Dawley rats, ischemic
brain injuries were induced on anesthetized (2% isoflurane) rats using a tMCAO model of
ischemic stroke as previously described (DiNapoli et al., 2008, 2010; Kelly et al., 2009;
Tan et al., 2013, 2015). Briefly, a 4–0 suture (#403956; Doccol Corp; Sharon, MA) was
inserted through the internal carotid artery into the right MCA to produce an ischemic
brain injury. Suture was removed after 2 h of ischemia to allow for reperfusion of the
infarcted area. After surgery, rats were administered 0.5 ml saline (i.p.) for fluid
replenishment and bupivacaine (1%; Sigma Chemicals; St. Louis, MO) was injected (s.c.)
at incision sites for pain relief. Rats were housed singly on fresh bedding with moistened
food and water placed on the floor of the cage overnight for ease of access. Laser Doppler
was used to establish relative cerebral blood flow (CBF) baseline and monitor for changes
in CBF over the 2 h ischemia. Inclusion/exclusion criteria were: (1) rat experienced less
than a 75% reduction in CBF from baseline after suture insertion; (2) rat experienced
restoration of CBF less than 80% of baseline upon reperfusion; (3) rat died before
assigned time point (age-related or MCAO-related); (4) perforation of cerebrovasculature
during suture insertion; (5) tumor present in location that prohibited successful MCAO
surgery; (6) rat placed on clinical call by West Virginia University vet staff after arrival but
before MCAO.
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Neurologic outcomes. Neurological functional assessments were carried out by
investigators blinded to treatment groups using standard operating procedures in the
WVU rodent behavior core. A modified Neurological Severity Scores (mNSS) and a
health/sickness screen were performed on rats (n = 12–13 rats per treatment) at 24 h
post-MCAO to evaluate impairments in motor, sensory, balance and reflex measures
during the acute period recovery following tMCAO, as previously described (Zhang et al.,
2002). The scoring range was from 0 to 20 points for the health/sickness behavior screen
and 0 to 18 points for the mNSS, with higher scores indicative of more severe impairment
(See Table 5.1 and 5.2).

Infarct volume and hemispheric swelling measurement. At 24 h after tMCAO, aged
female rats (5 rats per treatment) were anesthetized with 2% isoflurane, euthanized by
cardiac perfusion with 1× PBS, decapitated, brains removed and sliced coronally at 2 mm
intervals. Sections were incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma
Chemicals) for 20 min at 37 °C. Following TTC staining, infarct volumes were quantified
according to method previously described (Isayama et al., 1991). For anterior and
posterior side of each brain section, ischemic area, ipsilateral area and contralateral area
were outlined and infarct volume was calculated. Corrected infarct volumes were
calculated to avoid overestimation of infarct size using the equation: IV = (LA-[RA-RI]) x
d, where LA = area of left hemisphere (mm2), RA = area of right hemisphere (mm2), RI
= infarcted area (mm2) and d = slice thickness (2 mm). Hemispheric swelling (%) was
calculated, as an indicator of edema formation, according to previously described method
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(Isayama et al., 1991). Briefly, hemispheric swelling = (RV-LV) / LV. X 100%, where RV
= volume of right hemisphere (mm3) and LV = volume of left hemisphere (mm3).

Brain extraction, fixing and sectioning for microscopy studies. Rats (3–4 rats per
treatment) were deeply anesthetized with inhaled 4% isoflurane and transcardially
perfused with 1× PBS for 10 mins followed by perfusion with 4% paraformaldehyde (PFA)
for 5 mins before decapitation. The brains were extracted and sectioned using a brain
matrix. Each 2 mm section was post-fixed in 4% PFA overnight and cryoprotected in 30%
sucrose for 2 d. Sections were paraffin embedded, sectioned (5 μm) using a microtome
and plated onto microscope slides. For qualitative assessment, three to four slides
containing coronal sections from each subject in each treatment group were
deparaffinized and rehydrated using xylene and gradient ethanol (100%, 95%, 85%, 70%,
50%) baths. Section preparation and microscopic visualization was carried out as
described below. Sections were stored at −80 °C until used. For all assessments,
perilesional areas were determined using H&E-stained adjacent sections.

Iron content in the brain after tMCAO. At 72 h following tMCAO, female aged rats were
evaluated for iron content in the brain using brightfield microscopy of Perl's stained
sections with 3,3′ diaminobenzidine (DAB) enhancement. Re-hydrated sections were
rinsed three times in 0.1× PBS for 5 min and then stained in 1% potassium ferrocyanide/
0.1 N HCl for 40 min. Sections were rinsed three times in distilled water for 5 min and
then incubated in MeOH containing 0.01 M NaN3 and 0.3% H2O2 for 75 min. Sections
were rinsed twice in 0.1× PBS for 5 min then incubated in 0.025% 3,3’-DAB and 0.005%
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H2O2 in 0.1 N HCl for 40 min. Reaction was stopped by washing sections in 0.1× PBS.
Sections were mounted on slides, dehydrated in serial EtOH (25% to 100%) and cleared
with xylenes. Slides were cover slipped and visualized using an Olympus VS120 slide
scanning microscope. Once stitched images of brain sections were acquired, 4 images
of perilesional areas around the infarct from each section were viewed at 20×
magnification and non-heme iron visualized as dark brown/black granular staining.

Qualitative assessment of BBB impairment after tMCAO. At 72 h following tMCAO,
female aged rats were evaluated for changes in BBB extravasation of IgG using
immunohistochemistry. For IgG assessment of BBB leakage, re-hydrated sections were
fixed in 100% methanol for 3 min and then washed in 1× PBS. Endogenous peroxidases
were quenched by incubating sections in 3% v/v hydrogen peroxide in 1× PBS with 4%
v/v horse serum for 30 min. Sections were then washed 3 times in 1× PBS. Subsequently,
brain sections were permeabilized in 1% w/v TritonX-100 in PBS with 4% horse serum
for 1 h followed by washing 3 times in 1× PBS. Brain sections were stained for IgG by
incubating sections in horseradish peroxidase linked rat anti-IgG (1:500; HAF005; R&D
Systems; Minneapolis, MN) in 1× PBS with 4% horse serum for 2 h. Sections were
washed 3 times with 1× PBS. After staining, slides were cover slipped using FlouromountG (Southern Biotech; Birmingham, AL) and allowed to dry prior to imaging. Slides were
visualized by bright field microscopy using an Olympus MVX10 microscope (Pittsburgh,
PA).
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Qualitative assessment of lipid peroxidation and cell death after tMCAO. At 72 h
following tMCAO, aged female rats were evaluated for lipid peroxidation and apoptosis
using immunohistochemistry.
For assessment of lipid peroxidation, re-hydrated brain sections were fixed in 100%
methanol for 3 min and washed in 1× PBS. Brain sections were permeabilized using 1%
Triton X-100 in PBS with 4% horse serum for 1 h followed by washing 3 times in 1× PBS.
Brain sections were immunostained using a primary antibody for 4-HNE, a marker of lipid
peroxidation, (1:200; mouse, MAB3249; R&D Systems) and then incubated in the dark
overnight at 4 °C. The following day, the primary antibody was removed and slides were
washed 3 times in 1× PBS, prior to secondary antibody incubation. Sections were
incubated in secondary antibody (anti-mouse AlexaFluor 568 (1:1000; Invitrogen) for 2 h
in the dark at room temperature, washed 3 times in 1× PBS, cover slipped using
Flouromount-G with DAPI and imaged using an MIF Olympus Slide Scanner with a 20×
objective.
Apoptosis was assessed via terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) using a TUNEL system kit (DeadEnd™ Fluorometric; Promega)
according to manufacturer's instructions. The re-hydrated sections were washed in 0.85%
NaCl for 5 min followed by 1× PBS for 5 min. For apoptosis detection, the slides were
fixed with 4% PFA for 15 min followed by washing with 1× PBS two times for 5 min each.
The sections were permeabilized using 100 μl of Proteinase K solution for 10 min, washed
with 1× PBS for 5 min, fixed again in 4% PFA for 15 min and then washed with 1× PBS
for 5 min. Brain sections were allowed to equilibrate using 100 μl of equilibration buffer
for 10 min followed by labeling using 50 μl of TdT reaction mix containing nucleotide mix
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and rTdT enzyme for 1 h at 37 °C in a dark, humidified chamber. After incubating, the
reaction was stopped using 2xSSC for 15 min, followed by washing 3 times with 1× PBS
for 5 min. Finally, slides were mounted using the ProLong™ Glass Antifade Mounting
media with NucBlue™ stain containing DAPI and visualized using a Zeiss LSM 710
confocal microscope using 40× objective with constant exposure time for each marker in
all analyzed sections.

Microvessel isolation and brain distribution of NL-1 and NL-1 NP. To determine the
distribution of NL-1 and NL-1 NP into the brain, naïve rats were injected with NL-1 (10
mg/kg) or NL-1 NP (0.25 mg/kg) intravenously through the tail vein. After 1 h, rats (n = 3
rats per treatment) were anesthetized using 4% isoflurane, euthanized and brain
collected. The cerebellum olfactory bulbs, meninges and choroid plexus were discarded
and the left and right cortices underwent microvessel isolation as previously described
(Huber et al., 2002). Briefly, right and left cortex of each brain was dissected, weighed,
placed into a Dounce homogenizer with 4 ml of microvessel isolation buffer and
homogenized using 10 strokes with the pestle. The brain homogenate was centrifuged at
500 xg at 4 °C for 5 min to remove debris. Four ml of 26% dextran was added to the brain
homogenate and vortexed. The brain homogenate was centrifuged at 10,000 xg at 4 °C
for 30 min. One ml of the brain supernatant was placed into a 1.5 ml microfuge tube to
serve as microvessel-depleted brain homogenate. The remaining supernatant was
discarded and 4 ml of microvessel isolation buffer with 0.5% bovine serum albumin (BSA)
was added to resuspend the vascular pellet and filter the pellet through a 100 μm mesh
strainer. The filtered pellet solution was then filtered over a 40 μm mesh strainer and the
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vessels on the strainer were collected with 8 ml of microvessel isolation buffer with 0.5%
BSA. The resuspended pellet was centrifuged at 5000 xg at 4 °C for 10 mins. The
supernatant was discarded and microvessel pellet resuspended in 1 ml of microvessel
isolation buffer with 0.5% BSA and placed into a pre-weighed 1.5 ml microfuge tube. The
tube was then centrifuged at 5000 xg at 4 °C for 5 min. Tube weight was recorded and
isolated microvessel pellet was resuspended in 1 ml of microvessel isolation buffer. All
samples were stored at −80 °C until used.
Once all samples were obtained, samples were thawed and sonicated 3 times for 20 s.
For NL-1 isolation from samples, an equivalent volume of ethyl acetate was added,
vortexed and centrifuged at 5000 xg at 4 °C for 10 min. The ethyl acetate fraction was
then dried under flowing air and resuspended in 200 mL of acetonitrile for LC-MS/MS
quantification. Samples were analyzed using an ABSciex 5500 LC-MS/MS and compared
to a standard curve as described earlier (Culman et al., 2012). The standard curve
regression (r2) for this study was 0.99.

Statistical analysis. All data were acquired and analyzed by investigators blinded to
treatment groups. Data were reported as mean ± standard deviation (SD). Comparison
of mortality between groups was analyzed using the log-rank Mantel-Cox test with live
denoted as 0 and dead as 1. Infarct volume and hemispheric swelling were compared
between groups using one-way analysis of variance (ANOVA) with significance
determined using Tukey's HSD post hoc analysis. Health/sickness behavior screen and
mNSS were compared between groups using one-way ANOVA with repeated measures
(before and after MCAO) with significance determined using Tukey's multiple
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comparisons post hoc analysis. TUNEL positive cells that co-localized with DAPI positive
nuclei in the ipsilateral hemisphere were counted in selected area of the 40× micrograph
for each rat in each treatment. The total number of TUNEL positive cells from each
micrograph for each rat was combined and a mean of TUNEL positive cells for all rats
within a treatment were analyzed and plotted. Level of significance was set at p < 0.05.

RESULTS
Mortality and exclusion of rats from study. A total mortality rate of 30% from
experimental ischemic stroke with reperfusion was observed in this study with a total of
76 rats (23 vehicle, 22 NL-1 (0.25 mg/kg), 15 NL-1 (10 mg/kg) and 16 NL-1 NP) were
needed to complete the study. We used 49 rats (n = 12 for vehicle, NL-1 (0.25 mg/kg)
and NL-1 (10 mg/kg) and n = 13 for NL-1 NP) in the study and excluded 27 rats from the
study (21 for deaths before assigned time point after tMCAO (mortality) and 6 for other
reasons). Mortality rates at 24 h resulting from tMCAO with reperfusion for the four
treatment groups were: vehicle (45%; 10 of 22)), NL-1 (0.25 mg/kg) (40% (8 of 20)), NL1 (10 mg/kg) (14%: 2 of 14)) and NL-1 NP (7%; 1 of 14). A significant difference (p =
0.007) in mortality was noted between treatment groups. Pairwise comparison showed
significant differences (p < 0.01) between both the NL-1 (10 mg/kg) and NL-1 NP groups
as compared to the vehicle group. Additionally, the NL-1 (10 mg/kg) and NL-1 NP groups
showed a significant (p < 0.01) decrease in mortality compared to the NL-1 (0.25 mg/kg)
group. No differences (p > 0.05) were observed between the NL-1 (0.25 mg/kg) and
vehicle groups or between the NL-1 (10 mg/kg) and NL-1 NP groups. For the 6 rats
excluded from the study for other reasons, 1 from the NL-1 (10 mg/kg) group was
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excluded for having a tumor in a location that infringed on MCAO surgery, 3 (2 NL-1 (0.25
mg/kg) and 1 NL-1 NP) were assigned into treatment groups but excluded due to vet staff
issuing a clinical call before an MCAO surgery was performed and 2 (1 vehicle and 1 NL1 NP) were excluded for not meeting inclusion/exclusion criteria of achieving a ≥ 75%
decrease in CBF from baseline.

Changes in neurological functional assessment post-MCAO. Using the mNSS and
health/sickness behavior screen, we assessed the effects of NL-1 administration on
neurological recovery at 24 h after tMCAO. Results indicated no difference (p > 0.05) in
mNSS scores between either NL-1 (0.25 mg/kg) or NL-1 (10 mg/kg) and vehicle treatment
group (Figure 5.2A). A significant difference (p < 0.05) was found for treatment with NL-1
NP and vehicle treated rats. No difference (p > 0.05) in mNSS between NL-1 (10 mg/kg)
and NL-1 NP was shown (Figure 5.2A). A significant (p < 0.05) difference in the
health/sickness behavior screen was noted between both NL-1 (10 mg/kg) and NL-1 NP
when compared to vehicle treated rats (Figure 5.2B) but no difference (p > 0.05) between
NL-1 (0.25 mg/kg) and vehicle treated rats was found (Figure 5.2B).

Changes in infarct volume and hemispheric swelling post-MCAO. We assessed
effects of NL-1 administration on infarct volume and hemispheric swelling in aged female
rats at 24 h after 2 h tMCAO with reperfusion. Using 2 mm brain sections stained in TTC
(Figure 5.3A), we determined that NL1 (10 mg/kg) and NL-1 NP treated rats had
significantly reduced infarct volumes by 45% and 69%, respectively, when compared to
vehicle treated rats (Figure 5.3B). No difference (p > 0.05) in infarct volume was observed
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between NL1 (0.25 mg/kg) and vehicle treated rats (Figure 5.3B). A significant decrease
in hemispheric swelling of 35% in NL1 (10 mg/kg) and 59% in NL-1 NP treated rats was
demonstrated when compared to vehicle treated rats (Figure 5.3C).

Iron accumulation in the brain post-MCAO. Using Perl's stained brain sections with
DAB enhancement, we evaluated the effect of NL-1 and NL-1 NP treatment on
accumulation of non-heme iron in the brain at 72 h post-tMCAO. Figure 5.4A is a
representative micrograph of iron staining in the naïve brain of an aged rat. As the figure
depicts, there are a few areas of iron staining localized within neurons and around blood
vessels, which is a typical observation seen in aged rodents (Hagemeier et al., 2014).
Figure 5.4B illustrates a profound increase in iron accumulation in the brain at 72 h postMCAO in rats treated with vehicle. Rats treated with low dose of NL-1 (0.25 mg/kg)
showed increased iron accumulation in perilesional areas surrounding the infarct at levels
comparable to vehicle treated rats (Figure 5.4C). Figure 5.4D and E reveal a marked
decrease in iron staining in brain sections surrounding the infarct at 72 h post-stroke in
rats treated with NL-1 (10 mg/kg) and NL-1 NP, respectively.

Changes in BBB permeability post-MCAO. Changes in BBB permeability were
assessed at 72 h after post-MCAO using IgG immunostaining in brain sections. After the
brain was perfused, the only detectable IgG would be due to IgG that left the vascular
space. Figure 5.5 demonstrates a marked reduction in IgG levels after treatment with NL1 (10 mg/kg) and NL-1 NP as compared to vehicle. In contrast, NL-1 (0.25 mg/kg) showed
no reduction in IgG staining. To quantitatively assess improved BBB permeability
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observed in the NL-1 (10 mg/kg) and NL-1 NP treated rats at 72 h post-stroke, we
measured extravasation of sodium fluorescein (230 Da) and albumin (~65 kDa) using
fluorimetry analysis of brain homogenate. Results indicated no difference (p > 0.05) in
transient BBB permeability to sodium fluorescein or albumin at 72 h post-stroke in any of
the treated groups as compared to sham rats.

Changes in lipid peroxidation post-MCAO. At 72 h after tMCAO, levels of lipid
peroxidation were visualized by fluorescent immunostaining using 4-HNE as a protein
adduct marker. Figure 5.6 shows that 4-HNE staining was noticeably decreased in aged
rats treated with NL-1 (10 mg/kg) or NL-1 NP. NL-1 (0.25 mg/kg) did not provide
noticeable protection against lipid peroxidation as indicted by 4-HNE staining when
compared to vehicle treated rats.

Changes in TUNEL positive cells post-MCAO. At 72 h after tMCAO, the number of
TUNEL positive cells was markedly reduced in the NL-1 (10 mg/kg) and NL-1 NP treated
rats as compared to vehicle treated rats (Figure 5.7A). No change in the number of
TUNEL positive cells was visualized between NL-1 (0.25 mg/kg) treated rats and vehicle
treated rats (Figure 5.7A). Aggregate counting of TUNEL positive cells demonstrated that
treating rats with NL-1 (10 mg/kg) or NL-1 NP significantly (p < 0.0001) reduced the
number of TUNEL positive cells in rats as compared to vehicle and NL-1 (0.25 mg/kg)
treated rats (Figure 5.7B). Vehicle and NL-1 (0.25 mg/kg) treated rats showed a
significantly (p < 0.0001) higher number of TUNEL positive cells as compared to sham
rats (Figure 5.7B). No difference (p > 0.05) in TUNEL positive cells was measured
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between vehicle and NL-1 (0.25 mg/kg) treated rats. No difference (p > 0.05) in TUNEL
positive cells was shown for NL-1 (10 mg/kg) or NL-1 NP treated rats when compared to
sham rats (Figure 5.7B).

NL-1 concentration in rat brain microvessels. A starting bolus dose of NL-1 or NL-1
NP was administered through the tail vein to provide a starting NL-1 blood concentration
of 3.7 μM (NL−1) and 0.09 μM (NL-1 NP) for distribution. At 1 h after administration, the
brain was excised and microvessels were isolated from the brain parenchyma. Results
showed the brain concentration of NL-1 to be 287 ± 125 ng/ml in the NL-1 (10 mg/kg)
treated rats and 143 ± 29 ng/ml in the NL-1 NP treated rats. The concentration of NL-1 in
the isolated microvessels was 55 ± 10 ng/ml in NL-1 treated rats and 1693 ± 671 ng/ml
in NL-1 NP treated rats.

DISCUSSION
This was the first study to investigate the use of a mitoNEET ligand as an ischemic
stroke therapeutic in aged animals. Results from the study demonstrate that the
mitoNEET ligand, NL-1, significantly improved survival, reduced ischemia/reperfusion
injury at 24 h and decreased accumulation of parenchymal protein extravasation, lipid
peroxidation and cell death around the infarct area at 72 h after a 2 h ischemia with
reperfusion. Moreover, this study revealed that by nano-encapsulating NL-1 using PGLA,
an equivalent degree of protection as seen with NL-1 at 10 mg/kg could be produced
using a 40-fold lower dose of (0.25 mg/kg).
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MitoNEET is an outer mitochondrial membrane protein belonging to the zinc finger
protein family. The presence of a [2Fe-2S] cluster in the dimer allows for mitoNEET to act
as a redox active sensor that modulates mitochondrial bioenergetic function (Saralkar et
al., 2021). Previous studies showed that if mitoNEET were reduced in vivo, mitochondrial
deficits were observed, including disrupted oxidative phosphorylation, electron transport
chain deficits, increased ROS (hydrogen peroxide and superoxide) production and
ultrastructural changes in the mitochondrial cristae (Maier et al., 1998; Wiley et al., 2007).
These changes in mitochondrial function were accompanied by reduced expression of
the antioxidant defense proteins, superoxide dismutase 2 and glutathione peroxidase
(Geldenhuys et al., 2021). On the other hand, transgenic overexpression of mitoNEET
provided for improved mitochondrial bioenergetics, reduced inflammation and decreased
ROS production, as has been shown in other aged models of disease (Geldenhuys et al.,
2017; Chang et al., 2018; Joffin et al., 2021).
The mitoNEET ligand NL-1 was designed as a tool compound to study mitoNEET
physiology without PPAR-γ agonist activity (Colca et al., 2004, 2013; Kusminski et al.,
2012; Divakaruni et al., 2013; Nadareishvili et al., 2019). NL-1 was found to provide tissue
sparing effects in a mouse model of traumatic brain injury, an effect which was lost in
mitoNEET knockout (−/−) mice, as demonstrated by both immunohistochemistry and
behavioral measures; thus, supporting a mitoNEET-based mechanism of action (Yonutas
et al., 2020). Furthermore, mitoNEET ligand, TT01001 (Takahashi et al., 2015), was
recently shown to provide neuroprotection against subarachnoid hemorrhage in a rodent
model by preventing mitochondrial dysfunction (Shi et al., 2020). These findings provide
a robust scientific foundation for evaluating mitoNEET as a therapeutic target using a
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clinically relevant preclinical ischemic stroke model. In a previous study, we reported that
NL-1 administration provided protection against ischemia/reperfusion injury post-stroke
in young male mice (Saralkar et al., 2021). Furthermore, secondary off-target
pharmacology revealed that NL-1 did not appreciably interact with known kinases or
GPCR targets (Saralkar et al., 2021). These findings prompted us to evaluate NL-1 in a
model of cerebral ischemia/reperfusion injury using aged female rats. Since stroke is an
age-associated disease, it is critical to evaluate the effectiveness of any novel therapeutic
agent in an aged model of disease. As we have previously reported along with others,
brain injury and recovery after ischemic stroke is markedly different between aged and
young animals (DiNapoli et al., 2008, 2010; Kelly et al., 2009; Tan et al., 2013, 2015;
Tang et al., 2016; Spychala et al., 2018; Balseanu et al., 2020; Davis et al., 2020; Panta
et al., 2020; Banerjee et al., 2021). In the current study, we found that NL-1 was able to
provide significant protection in aged female rats against cerebral tissue damage induced
by tMCAO with reperfusion. A caveat to our findings is that we only evaluated aged female
rats due to reduced sexual dimorphism in weight between aged females as compared to
aged males. Whereas, young males are often preferred over young females due to
confounding issues with estrus cycle, in studies using aged females, which are
reproductively senescent, they are more comparable in weight to younger females; thus,
reducing confounding factors of needing to adjust surgical parameters (i.e. filament
diameter and length, percentage of anesthesia, volume of fluid replacement) as would
need to be done in comparative studies between aged female and aged male rats. In
follow-up experiments, aged male rats will be included to evaluate for sex as a biological
variable, as several recent studies suggest important differences in ischemic stroke
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progression and recovery are sex dependent (Manwani et al., 2015; Cohan et al., 2019;
Seifert et al., 2019; El-Hakim et al., 2021). As an aside, we have now reported positive
findings of NL-1 as a central acting mitoceutical in young and aged, male and female,
mice and rats and following ischemic stroke and traumatic brain injury; thus, suggesting
that modulation of mitoNEET effectively reduces mitochondrial dysfunction postneurological injury, regardless of these variables (Yonutas et al., 2020; Saralkar et al.,
2021).
A common measure of neuroprotection following preclinical stroke is functional
improvement as measured using a composite neurological scale. These measures are
typically performed starting at 24 h after MCAO and can be as simple as the Bederson
scale (Bederson et al., 1986), which evaluates forearm flexion, resistance to lateral push
and circling to more sophisticated neurological scales, such as the mNSS, which
evaluates multiple neurological parameters, including motor, sensory, reflex and balance
(Zhang et al., 2002). Unfortunately, these neurological scales, which rely heavily on
changes in sensorimotor performance, have proven to be ineffective at discerning poststroke improvements in stroke outcomes in aged rodents (Turner et al., 2012). The
sickness behavior scale reduces the impact that diminished motor function and
coordination has on post-stroke functional assessments in aged rodents. The sickness
behavior scale tracks changes in physical status (body weight/temperature and
food/water consumption), self-care (appearance, grooming, posture) and social
parameters (home cage activity and social interactions). By tracking changes in these
measures, more subtle changes in neural injury progression and recovery can be
discerned even by aged rodents. In this study, scores on the mNSS indicated that only
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the NL-1 NP group displayed any improved functional outcome at 24 h post-tMCAO with
reperfusion; however, the overall improvement in health of the rat at 24 h post-tMCAO
was potentially masked in the NL-1 (10 mg/kg) and NL-1 NP treatment groups as motor
and balance assessments were obscured by the lack of movement and hesitancy
observed in the aged rats even before MCAO. The sickness scale scores showed a more
robust improvement post-stroke for both the NL-1 (10 mg/kg) and NL-1 NP groups as
compared to vehicle treated rats.
NL-1 has been previously reported to provide protection against oxygen-glucose
deprivation, mimicking reperfusion injury, in murine vascular endothelial cells (bEnd3
cells) (Saralkar et al., 2020). The bEnd3 cells are routinely used as a BBB model, as they
form similar tight junctions and selective permeability of small organic molecules
(Geldenhuys et al., 2015; Dubey et al., 2019). In our stroke model using aged rats, we
found similar evidence of BBB augmentation with use of NL-1. The vascular marker, IgG,
was elevated at 72 h after experimental stroke with reperfusion in the brains of rats treated
with vehicle, which is indicative of increased IgG accumulation due to BBB disruptions
over the 72 h. NL-1 and NL-1 NP treatments attenuated extravasation of IgG at the BBB,
suggesting that the protection seen after ischemic stroke may, in part, be due to
preservation of BBB function. Increased hemispheric swelling, as indicated by IgG
accumulation in the infarct, post-stroke has been associated with deleterious effects on
neuronal survival (DiNapoli et al., 2008), as well contributing to the vascular dementia
seen in patients who survive a stroke (Nwafor et al., 2019; Sarvari et al., 2020). Due to
NL-1 being shown to have moderate BBB permeability in the mouse, we formulated NL1 into PLGA-based nanoparticles to improve tissue distribution due to a short half-life (<3
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h) (Saralkar et al., 2020, 2021). The promising results in vitro led us to evaluate the impact
formulation of NL-1 into a NP would have on preventing ischemia/reperfusion post-stroke.
NPs have been shown to improve the neuroprotective activity of select agents by several
other groups, providing support for pursuing this avenue of drug delivery to the CNS
(Mdzinarishvili et al., 2013). We found that NL-1 NP allowed for a 40-fold reduction in
drug dosing, from 10 mg/kg to 0.25 mg/kg with equivalent protection post-stroke. The
improved outcomes observed with the lower dose NPs suggest that NL-1 is either not
reaching the CNS in sufficient concentration as in vitro studies indicated or delivery to
endothelial cells that comprise the BBB is more substantive in the mechanism of action
than initially postulated. Since mitochondrial dysfunction in cerebral microvessels has
been shown to play a role in BBB breakdown and increased permeability, targeting
mitochondrial dysfunction as a therapeutic target to improve bioenergetics could be a
novel approach for ischemic stroke treatment. While evidence suggests that NL-1
improves endothelial cell function, it is also possible that the therapeutic effect of NL-1
occurs at other brain cell types, such as neurons or astrocytes, and that improvements in
BBB functional integrity and diminished edema formation are an indirect beneficiary of
these effects; Prior data indicates that cerebral endothelial cells are almost 4 times more
susceptible than neuronal cells and 16 times more susceptible than astrocytes to ironinduced mitochondrial dysfunction (Gaasch et al., 2007); thus, the findings that NL-1 and
NL-1 NP were found in high concentration in the isolated cerebral microvessels, 16% of
total brain NL-1 concentration in NL-1 (10 mg/kg) treated rats and 92% of total brain NL1 concentration in NL-1 NP treated rats, may point to improved endothelial cell function
playing a role in the beneficial effects of NL-1 treatment post-stroke. Future studies will
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probe, at a mechanistic level, how the modulation of mN within cerebral endothelium
impacts mitochondrial bioenergetics and antioxidant capacity, especially as it applies to
barrier functions and gain a clearer understanding of the pharmacokinetic profile of
nanoencapsulated NL-1.
Mitochondrial dysfunction occurring following ischemic stroke with reperfusion
results in a significant increase in lipid peroxidation. A primary driver of cellular lipid
peroxidation and an indicator of mitochondrial dysfunction is excessive iron accumulation
in the brain. Results of our study, show a profound increase in iron accumulation in the
perilesional area in vehicle and NL-1 (0.25 mg/kg) treated rats as compared to naïve
control rats. This marked increase was effectively mitigated in rats treated with NL-1 (10
mg/kg) or NL-1 NP; thus, suggesting that mitochondrial performance in cells near the
infarct were improved with NL-1 treatment. One of the byproducts of oxidative stress is 4HNE, which contains aldehyde functionality to form protein adducts (Osakada et al.,
2021). Proteomic analysis has indicated that mitoNEET, which is rich in lysines, binds
covalently with 4-HNE resulting in changes in the redox character of the [2Fe-2S] clusters
(Arnett et al., 2019). When rats were treated with NL-1 (10 mg/kg) or NL-1 NP, there was
a noticeable reduction in 4-HNE staining. Since elevated levels of 4-HNE contribute to
neuronal cell loss, this reduction in 4-HNE observed may be a prognostic biomarker of
the overall tissue sparing seen with NL-1 and NL-1 NP treatment.
To limit confounding factors, such as increased hemorrhage risk and spontaneous
recanalization, these studies targeted a 2 h ischemic brain injury with reperfusion. Thus,
these studies modeled an ischemic brain injury eligible for recanalization with tissue
plasminogen activator, which accounts for 3–7% of stroke patients. Future studies will be
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performed to establish applicable therapeutic time window out to at least 6 h after onset
of ischemia. In addition, we will probe the effects of permanent occlusion (majority of
ischemic strokes) on NL-1 efficacy; however, we postulate the effects will be diminished
based on prior results of permanent MCAO in young male mice (Saralkar et al., 2021).
Finally, future studies will extend the post-stroke evaluation period out to several weeks
to months to evaluate long-term recovery. Based on the results of these studies,
especially the marked reductions in mortality and edema observed, we posit that it is
highly likely these changes in the degree of ischemic brain injury will not be transient but
will represent marked improvements in recovery that extend into the chronic phase of
post-stroke recovery.

CONCLUSION
In this study, we report for the first time that the therapeutic use of the mitoNEET
ligand NL-1 at a dose of 10 mg/kg resulted in a marked improvement in survival,
attenuated infarct volume and reduced hemispheric swelling at 24 h after tMCAO with
reperfusion in aged female rats. Moreover, when NL-1 was encapsulated in PGLA
nanoparticles, this therapeutic benefit was again produced at a dose that was 40-fold less
than unencapsulated NL-1. The improved measures of functional outcome using a
sickness scale along with improved BBB function and reduced indicators of oxidative
stress reinforce the therapeutic potential of probing mitoNEET for treatment of ischemic
stroke with reperfusion. Showing the robust efficacy of NL-1 in aged rats is particularly
important as ischemic stroke is a disease of the elderly and the prior failures of many
stroke neuroprotectants was due, in part, to use of animal models that did not reflect the
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population most vulnerable to ischemic stroke. Taken together, mitoNEET represents a
novel drug target in reperfusion-injury post stroke that warrants further investigation.
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Figure 5.1. Structure of the mitoNEET ligand, NL-1.
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Figure 5.2. Neurological assessment of NL-1 treatment at 24 h post-tMCAO with
vehicle, NL-1 (0.25 mg/kg), NL-1 (10 mg/kg) and NL-1 nanoparticles (0.25 mg/kg). (A)
mNSS behavior and (B) health/sickness scale (⁎p < 0.05). Data reported as mean ± S.D.
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A

B

Figure 5.3 Effect of NL-1 treatment on infarct volume and hemispheric swelling. (A)
Representative TTC stained brain sections for vehicle, NL-1 (0.25 mg/kg), NL-1
(10 mg/kg) and NL-1 nanoparticles. Effect of NL-1 and NL-1 nanoparticle treatment on
(B) infarct volume and (C) hemispheric swelling at 24 h after tMCAO (⁎ denotes difference
compared to vehicle, # denotes difference compared to NL-1 (0.25 mg/kg) and $ denotes
difference
compared
to
NL-1
(10 mg/kg); ##,$$p < 0.01, ⁎⁎⁎, ###p < 0.001, ⁎⁎⁎⁎,
####p < 0.0001). (n = 5 rats/treatment). Data reported as mean ± S.D.
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Figure 5.4. Effect of NL-1 on iron accumulation in the brain. At 72 h following tMCAO,
iron content in perilesional areas of the brain were visualized in sections stained using
Perl's method with DAB enhancement. All brain sections were assessed in comparison
to (A) sham and (B) vehicle treated rats. Treatment groups consisted of (C) NL-1 (0.25
mg/kg), (D) NL-1 (10 mg/kg) and (E) NL-1 NP treated rats. Sections were visualized at
20× using a brightfield microscope. n = 3–4 rats/treatment.
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Figure 5.5. Qualitative assessment of NL-1 treatment on IgG extravasation. At 72 h
following tMCAO, extravasation of IgG in the brain was visualized in sections using
immunohistochemistry. Brain sections were assessed in comparision to (A) vehicle
treated rats. Treatment groups consisted of (B) NL-1 (0.25 mg/kg), (C) NL-1 (10 mg/kg)
and (D) NL-1 NP treated rats. Sections were visualized at 20× using a brightfield
microscope. N=3-4 rats/treatment.
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Figure 5.6. Qualitative assessment of NL-1 treatment on 4-HNE protein adduct
staining. At 72 h following tMCAO, lipid peroxidation in the brain was visualized using
immunofluorescence for 4-HNE. Brain sections were assessed in comparison to (A) sham
and (B) vehicle treated rats. Treatment groups consisted of (C) NL-1 (0.25 mg/kg), (D)
NL-1 (10 mg/kg), and (E) NL-1 NP. Sections were visualized at 20× using an
epifluorescent microscope. n = 3–4 rats/treatment.
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Figure 5.7. Effect of NL-1 treatment on apoptosis. At 72 h following tMCAO, cell death
(apoptosis) in the perilesional areas surrounding the core of the infarct were (A) visualized
using an immunofluorescent TUNEL staining kit. Brain sections were assessed in
comparison to vehicle treated rats. Treatment groups consisted of NL-1 (0.25 mg/kg), NL1 (10 mg/kg), and NL-1 NP. Sections were visualized at 40× using a confocal microscope.
n = 3–4 rats/treatment. (B) Quantitation of number of TUNEL positive cells was
performed. **** denotes p < 0.0001 difference compared to sham. ### and #### denotes
p < 0.001 and p < 0.0001 difference compared to vehicle treated rats. $$$ denotes p <
0.001 difference compared to NL-1 (0.25 mg/kg). n = 3–4 rats/treatment. Data reported
as mean ± S.D.
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Table 5.1 Health/sickness screen scale
Parameter
General
Appearance

Posture

Body Condition

Respiration

Body
Temperature

Body Weight

Spontaneous
Locomotion/Social
Interaction

Observation
Normal
Groomed, healthy appearing fur, pink mucous membranes and ear lobes
Mild Abnormal
Mildly rough/scruffy/dull fur, slightly less well-groomed, light pink mucous membranes/ear lobes, minimal
porforin staining, slightly squinted eyes
Moderate Abnormal
Rough/scruffy fur, piloerection, poor grooming, pale mucous membranes, and ear lobes, squinted eyes
Severe Abnormal
Very rough fur, no evidence of grooming, white mucous membranes, and ear lobes, substantial porforin
staining, severely squinted or closed eyes
Normal
Slight Hunch
Spine slightly curved
Moderate Hunch
Spine curved, paws slightly under body
Severe Hunch
Spine dramatically curved, paws tucked under body, head angled downward
Normal
Thin
Slight segmentation of vertebrae, dorsal pelvic bones are more prominent, slight dehydration (skin pinch
test response is slightly delayed)
Emaciated
Prominent vertebrae and skeletal bones that are readily palpable, dehydrated (skin pinch test results in skin
remaining tented)
Normal
Altered
Increased rate and/or effort
Abnormal/Distressed
Very increased rate or gasping/labored breathing, irregular
Normal/No change
1-4 degree C
5-8 degree C
9-12 degree C
0-5% change
5.1-10% change
10.1-15% change
15.1-20% change
> 20.1% change
Normal
Active and interacting with cage-mate(s)
Mild Abnormal
Still spontaneous activity and some peer interaction but reduced
Moderate Abnormal
Lethargic (may need probing via tapping on cage or cage tilt) and minimal peer interaction
Severe Abnormal
Immobile and no peer interaction
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Score
0
1

2
3

0
1
2
3
0
1

2

0
1
2
0
1
2
3
0
1
2
3
4
0
1
2
3

Table 5.2: Modified Neurologic Severity Scale (mNSS)
Subtest

Score

1. Reflex test

3

Corneal Reflex – lack of eye blink when cornea is touched

1 (0.5/eye)

Pinna Reflex – lack of head shake when pinna is touched

1 (0.5/ear)

Startle – lack of jumping, freezing, moving when loud noise is heard

1

2. Walking test

3

Normal

0

Inability to walk straight

1

Circling/falling toward paretic side

2

Immobile (despite probing)

3

3. Placing test

3

Visual- lack of placement

1 (0.5/paw)

Tactile – lack of placement

1 (0.5/paw)

Proprioceptive – lack of placement

1 (0.5/paw)

4. Beam balance test

6

Balances steadily or traverses beam to clamp

0

Grasps sides of beam but is generally steady

1

Balances unsteadily, hugs beam and/or 1 limb slips/falls down

2

Balances unsteadily, hugs beam, 2 limbs slip/fall down

3

Attempts to balance but very unsteady, falls under beam but recovers

4

Attempts to balance but spins, clings to underside of beam

5

No attempts to balance

6
5. Inverted test

3

Forelimb flexion or limb not moving to aid with balance

1

Hindlimb flexion or limb not moving to aid with balance

1

Head moved more than 10 degrees from vertical center or persistent spin

1

Total
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Chapter Six
GENERAL DISCUSSION
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SUMMARY

In the last decades tremendous advances in the field of biomedical sciences have
increased the life span of individuals. As a consequence, there is growing number of older
people (>65 years) living with chronic diseases and disability. In spite of age being the
most important risk factor for diseases such as cancer, heart disease, neurodegenerative
conditions, osteoporosis, arthritis, diabetes, sarcopenia and macular degeneration
(Kirkwood and Tipton, 2017), older patients are generally underrepresented in clinical
trials. Drugs showing efficacy in younger population may have completely different
outcomes (adverse reactions) when tested in elderly. This might be due innate irreversible
physiological alterations occurring due to aging which may ultimately manifest in chronic
diseases. Therefore, it is pivotal to understand the biology of aging as well as characterize
the effects of aging in healthy and pathological conditions, which is the focus of this
dissertation. This knowledge will aid in the drug development process and thus may
significantly improve the translational potential of novel therapeutic agents for the
treatment of age-related chronic diseases.

The process of CNS drug development is challenging and time consuming. The
success of CNS clinical trials can be improved by gaining a clear understanding of
pathophysiology of CNS diseases as well as adverse side effects of the drugs on the
CNS. Additionally, evaluating the efficacy of drugs to cross the BBB is utmost important
in determining CNS therapeutic outcomes. One of the focus areas of our lab is studying
the in vivo efficacy of therapeutic candidates using clinically relevant neuronal injury
models. In the past, we have extensively studied the neuroprotective effects of bryostatin-
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1, a PKC modulator for the treatment of cerebral ischemia and TBI. In vitro and in vivo
studies conducted by others reported enhanced synaptogenesis, improved cognition, antinflammatory effects. Additionally, bryostatin-1 has shown to be effective in treatment of
HIV-1 brain infection by eradicating CNS viral reservoirs. Bryostatin-1 has not only shown
to penetrate the BBB and exert its actions but also has minimal adverse effects at
therapeutic (low-moderate) doses. Following favorable outcomes in pre-clinical studies,
bryostatin-1 has recently progressed to human trials for the treatment of MS, AD and
Fragile X syndrome.

While age is considered a primary risk factor for neurological diseases/disorders,
it is also a major determinant in the development and testing of pharmacological
compounds targeting the CNS by altering the drug exposure and therapeutic outcomes.
The process of biological aging affects every cell, tissue, and organ leading to anatomical,
immunological, and physiological changes in our body. Given the importance of structural
and functional decline in the CNS as well as immunosenescence in impacting
neurodegeneration, the main goal of this dissertation was to

1) Characterize the age-related differences on cerebrovascular topology
2) Characterize the age-related differences on peripheral immune response
following systemic infection
3) Test the therapeutic efficacy of a novel ligand NL-1, in the aged rodent model
of cerebral ischemia reperfusion injury

This chapter concludes with a brief summary and suggestions for future experiments.
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Brain vasculature dictates the supply of oxygen and nutrients and is essential for
normal cellular metabolism. However, with advancing age, the cerebral vascular network
undergoes structural and functional remodeling affecting the neuronal microenvironment.
Several studies have proposed that dysfunctional vasculature precedes cognitive decline
as seen in case of AD. So, we first sought to characterize differences in the morphology
of cortical vasculature of young versus aged female rats using classical angiographic
methods. Additionally, we evaluated the complexity of cortical vessel network using
lacunarity measures. Once we analyzed differences in global cortical vessel structure, we
also wanted to quantify the degree to which these classic vessel parameters are altered
in the middle cerebral artery (MCA), the major artery supplying blood to the brain. We
found reduced vessel density, increased lacunarity and decreased complexity at global
level as well as at MCA level. The results from this study confirmed that the cerebral
vasculature structure is modified due to aging which could potentially alter brain perfusion
contributing to the pathophysiology of age-related neurological disorders.

After understanding the changes occurring at the cerebrovascular architecture with
increasing age, we next moved on to quantifying age-related alterations in the peripheral
immune system. The immune system is vital in maintaining homeostasis and providing
protection against foreign pathogens. With advancing age, the immune system
undergoes a remodeling process termed as immunosenescence which contributes to
increased vulnerability to cancer, autoimmune diseases, and infections. Additionally,
aged immune system is prone to systemic chronic low-grade inflammation – termed as
inflamm-aging. Still, what remains unknown is, how the immune system reacts to
systemic inflammation in aged subjects. Therefore, we wanted to determine the
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composition of key leukocyte population in circulation as well as spleen due to aging in
rodents. We also investigated the expression levels of cytokines and chemokines in
plasma following LPS induced acute systemic inflammation at two different time points 3 and 24h. Given the importance of spleen in hosting a range of immunological functions,
we found significant immunosuppression in the spleen of aged female rats irrespective of
treatment suggesting reduced capacity to retain the immune cells due to aging. We also
revealed dysregulated cytokine/chemokine levels in the aged animals confirming the
presence of age-related immunosenescence and inflamm-aging phenotype. Taken
together, these findings are in line with previous literature and underscore the importance
of using age-appropriate animals while studying specific diseases.

Lastly, we wanted to test the therapeutic efficacy of a novel pharmacological agent
in an age-related neurological disease in vivo. Case in point is cerebral ischemia, which
disproportionally affects the elderly leading to increased death and disability. Till date,
reperfusion with tPA remains the golden standard for the treatment of stroke. However, it
has narrow therapeutic window (3-4.5h after onset) and not everyone is eligible to receive
the drug. Over the years, several pharmacological agents have been developed and yet
not a single candidate has shown efficacy in the clinics. Therefore, there exists an urgent
need to develop therapeutics alone or in combination with tPA for the treatment of
cerebral

ischemia.

Mitochondrial

dysfunction

plays

a

central

role

in

the

neurodegeneration following ischemic-reperfusion injury. MitoNEET (mN), an outer
mitochondrial membrane protein has been shown to regulate bioenergetic capacity by
acting as a redox and pH sensor. Previous studies showed that targeting mN using a
novel ligand called NL-1 has demonstrated neuroprotective effects following cerebral
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ischemia, traumatic brain injury and Parkinson’s disease. In the current study, we
hypothesized that by potentiating mitochondrial activity, neuronal survival in the
penumbra will be enhanced leading to smaller infarcts and improved functional outcomes.
We tested the therapeutic outcomes of two doses of NL-1 as well as nanoparticle
formulation of the drug in an aged female rat model of cerebral ischemia/reperfusion
injury. We found significant reduction in infarct volume and hemispheric swelling in a
dose-dependent manner. Interestingly, the nanoparticle encapsulated NL-1 at 0.25mg/kg
showed improved therapeutic outcomes. In addition, NL-1 administration decreased
oxidative stress as well as neuronal apoptosis in the penumbra region at 72h following
stroke indicating its neuroprotective effects. This correlated with possible rescue of BBB
function as evidenced by reduced IgG accumulation in the brain parenchyma upon NL-1
treatment. These results demonstrated that targeting mitoNEET via NL-1 holds promise
as a novel strategy for the treatment of cerebral ischemia reperfusion injury.

FUTURE DIRECTIONS

Owing to various ethical reasons, studying aging on humans is difficult and so
rodents are the preferred models to study age-related diseases. Future studies should
focus on better modelling of neurological diseases in order to improve the translational
potential of preclinical research. With advancing age, a great body of work research is a
being performed to understand the evolution and mechanism of biological aging. The
initial step toward developing novel therapeutics is to gain a detailed understanding of the
cellular and molecular processes that promote or delay aging. Additionally, follow up
studies

are

required

to

identify

the
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potential

links

between

neurological

disorders/diseases and hallmarks of aging. Elucidation of these pathways will open up
new treatment avenues. However, therapeutic interventions targeting a single pathway
may not be successful. A combination of improved multimodal approach will be necessary
for effective treatment of age-related chronic diseases.
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